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Abstract 
Receptors embedded in the plasma membrane serve to relay signals from the 
outside to the inside of the cell and regulate cell growth and differentiation. Disruption of 
these signals can occur by mutation or abnormal expression of receptor proteins.  These 
disruptions can result in aberrant cell growth and are found in many cancers.  As a result, 
cell surface receptors are common targets of directed small molecule and biologic 
therapeutics.  Two such targeted receptors are Smoothened (Smo) and the Epidermal 
Growth Factor Receptor (EGFR).  Mutations in Smo are found in basal cell carcinoma, 
meningiomas and medulloblastoma.  Overexpression or mutations of EGFR are found in 
glioblastoma and non-small cell lung cancer.  Approved therapeutics targeting Smo and 
EGFR are currently used in the clinic, but acquired resistance to both Smo and EGFR 
targeted therapeutics generally occurs within months or at most a few years.  More 
precisely defining the molecular mechanisms of activation and inhibition of these two 
receptors is of both fundamental interest as well as critical to understanding and 
improving current targeted therapeutics.  
 Ligand-induced dimerization of receptor tyrosine kinases (RTKs) is a generally 
accepted mechanism of activation for all classes of RTKs except the Insulin Receptor 
(IR) family.  In contrast to all other RTK families, IR family members exist as preformed 
disulfide linked dimers on the cell surface.  Recent evidence suggests that the ectodomain 
(ECD) of IR, and its homolog the type 1 insulin-like growth factor receptor (IGF1R), 
maintains separation of subunit transmembrane regions in the absence of ligand.  Ligand 
binding releases this ectodomain autoinhibition and allows the transmembrane domains 
to come together and the intracellular kinase domains to transphosphorylate.  Parallels 
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between the IR/IGF1R mechanism of activation and ligand-induced dimerization 
suggested that the IR/IGF1R ECDs may be able to regulate other families of RTKs, and 
we set out to understand how the IR/IGF1R activation mechanism relates to EGFR 
activation.  We find that the IR/IGF1R ECD fails to activate the kinase domain of EGFR 
in either IR-EGFR or IGF1R-EGFR chimeric receptors.  In contrast, the EGFR ECD is 
able to activate the IR kinase domain in an EGFR-IR fusion in an EGF-dependent 
fashion.  The IR and EGFR mechanisms of activation thus appear to share some but not 
all features. 
Despite years of intensive study and its central importance to animal development 
and human health, our understanding of the Hedgehog (Hh) signaling pathway remains 
riddled with gaps, question marks, assumptions, and poorly understood connections.  In 
particular, understanding how interactions between Hh and Patched (Ptc), a 12-pass 
integral membrane protein, lead to modulation of the function of Smo, a 7-pass integral 
membrane protein, has defied standard biochemical characterization.  Recent structural 
and biochemical characterizations of Smoothened domains have begun to unlock this 
riddle, however, and point towards improved cancer therapies.  We present purification 
and biochemical characterization of near full-length Smo protein in the presence of small 
molecules targeting multiple Smo domains.  These studies were carried out with the aim 
of developing the tools necessary to understand the molecular mechanisms governing 
Smo activity. 
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Chapter 1. How IGF1 Activates Its Receptor 
 
Acknowledgements  
Chapter 1 contains the published manuscript by Kavran et al, 2014 in the journal 
eLife.  My primary contribution was analyzing the importance of specific IGF1R kinase 
domain surfaces for receptor activation.  I designed and cloned clusters of IGF1R kinase 
domain surface mutants.  I established a cell based assay used to determine the role of 
these clusters in receptor activation (Figure 1.11).  This work identified two distinct 
surfaces on the IGF1R kinase domain that disrupt receptor activation but showed that 
IGF1R does not activate via an EGFR-like asymmetric kinase dimer.  The cell based 
assay was later adapted for use in cysteine substitution experiments probing association 
of IGF1R transmembrane regions during receptor activation. 
 
Abstract 
The type I insulin-like growth factor receptor (IGF1R) is involved in growth and 
survival of normal and neoplastic cells. A ligand-dependent conformational change is 
thought to regulate IGF1R activity, but the nature of this change is unclear. We point out 
an underappreciated dimer in the crystal structure of the related Insulin Receptor (IR) 
with Insulin bound that allows direct comparison with unliganded IR and suggests a 
mechanism by which ligand regulates IR/IGF1R activity. We test this mechanism in a 
series of biochemical and biophysical assays and find the  IGF1R ectodomain maintains 
an autoinhibited state in which the TMs are held apart. Ligand binding releases this 
constraint, allowing TM association and unleashing an intrinsic propensity of the 
intracellular regions to autophosphorylate. Enzymatic studies of full-length and kinase-
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containing fragments show phosphorylated IGF1R is fully active independent of ligand 




 Ligand binding to IR and IGF1R extracellular regions (ECDs) stimulates receptor 
kinase activity, leading to phosphorylation of multiple substrates and initiation of specific 
signaling cascades (Siddle, 2012). IR family members are unique among RTKs in 
forming constitutive dimers (of αβ subunits). Dimerization per se thus cannot be the 
activating signal, and activation is thought to involve a ligand-dependent conformational 
change (Frattali, 1992; Lemmon and Schlessinger, 2010). Part of the function of the ECD 
appears to be maintaining an inactive state in the absence of ligand as tryptic removal of 
the IR ECD results in constitutive activity (Tamura, 1983; Shoelson, 1988). 
Two ligand-binding sites are present in each αβ dimer. Each site is composed of 
two distinct partial sites known as ‘Site 1’, which is composed of residues on L1 from 
one subunit and residues on the αCT′ helix of the other subunit (a prime is used to 
indicate the opposite subunit), and ‘Site 2’, which is com-posed of residues on Fn1′ and 
Fn2′ (Williams, 1995; Mynarcik, 1996; Whittaker, 2001, 2008; Smith, 2010) (Figure 1.2). 
A classic feature of ligand binding to IR and IGF1R is negative cooperativity (De Meyts, 
2004), which implies communication between the two sites such that ligand binding to 
one site generates an asymmetric state of the receptor in which the affinity of the second 
site for ligand is weakened. The nature of this asymmetric state is not known, but 
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hydrogen–deuterium exchange experiments with IGF1R identified regions that are likely 
foci of this asymmetry (Houde and Demarest, 2011). 
Crystal structures of the unliganded ECD of IR (McKern, 2006; Smith, 2010) and 
a fragment of the IR ECD bound to Insulin (Menting, 2013) have greatly aided efforts to 
under-stand the molecular mechanisms governing IR/IGF1R activity. In the absence of 
ligand, the αβ subunits of the ECD form a symmetric, antiparallel dimer shaped like an 
inverted ‘V’ (Figure 1.4A). The apex of this ‘V’ is formed by reciprocal interactions 
between L2-Fn1 domain pairs from opposing subunits (Figure 1.4C), with the Fn2 and 
Fn3 domains (Fn2–3) forming ‘legs’ with C-termini separated by 117 Å. The fragment of 
IR crystallized with Insulin encompassed the first four domains of the ECD (L1-CR-L2-
Fn1) with the αCT peptide fused to the C-terminus of Fn1. The structure of this fragment 
revealed the interaction between Site 1 and Insulin and rationalized a wealth of 
biochemical data. The nature of the activating conformational change in IR remained 
unclear, however, owing to the absence of the Fn2-ID-Fn3 regions, which contain Site 2, 
and the presence of an apparently nonphysiological dimer mediated by αCT regions 
(Menting, 2013). Current models of IR/IGF1R activation envision only minor structural 
rearrangements of the ECD when ligand binds and posit a ligand-dependent twist of the 
Fn2–3 domains with little change in TM separation as the activating signal (Ward and 
Lawrence, 2012; Ward, 2013). 
Although structural and mechanistic details of ligand-dependent activation of the 
receptor remain unclear, autophosphorylation of the kinase domain is a key element of 
receptor activation. Early studies with purified IR showed that autophosphorylation 
enhances IR kinase activity and that addition of Insulin led to a threefold to fivefold 
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increase in Vmax with no change in Km for peptide substrate (Kasuga, 1983; Pike, 1986). 
More recent studies with isolated IGF1R kinase domains showed little phosphorylation of 
peptide substrates in the absence of autophosphorylation but increased activity with each 
successive trans-autophosphorylation of the three tyrosines in the kinase activation loop 
(Favelyukis, 2001) (Figure 1.3). Crystal structures of IR and IGF1R kinase domains in 
both inactive and active, phosphorylated conformations revealed canonical kinase domain 
features and rationalized how autophosphorylation promotes the active conformation 
(Hubbard, 1994; Hubbard, 1997; Favelyukis, 2001; Huse and Kuriyan, 2002; Munshi, 
2002). A specific asymmetric dimer of kinase regions is necessary for activation of the 
Epidermal Growth Factor Receptor (EGFR) (Zhang, 2006), a related RTK, but whether 
or how kinase domain interactions play a role in regulating IR/IGF1R activity is not 
known. 
To address the gaps in our understanding of the molecular mechanisms 
underlying IR family activation, we inspected crystal structures of the IR ECD for clues 
to the nature of conformational changes that occur when ligand binds. We identified an 
underappreciated dimer of the IR ECD fragment with Insulin bound that preserves key 
inter-subunit interactions present in the unliganded IR ECD and illuminates 
conformational changes that occur when ligand binds. In particular, an inter-subunit 
interaction that stabilizes the separation of the Fn2–3 ‘legs’ of the ECD is disrupted by 
ligand binding, suggesting that TM separation may be important for maintaining the 
receptor in an inactive state. We tested this model in a series of biochemical and 
biophysical assays and show that the IGF1R ECD indeed autoinhibits activity by holding 
the TMs apart in the absence of ligand. Ligand binding releases this autoinhibition and 
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allows the TMs to come together in an autophosphorylation-competent state. Enzymatic 
activity assays of purified, full-length IGF1R and several kinase-domain containing 
IGF1R fragments further show that, once phosphorylated, IGF1R is fully active 
independent of ligand or allosteric stimulation. The key step regulated by ligand binding 
is thus autophosphorylation and not kinase activity per se, and the role of the IR/IGF1R 
ECD is to inhibit activity in the absence of ligand rather than promote activity in the 
presence of ligand. 
 
Materials and Methods 
Expression and purification of the IGF1R kinase domain (IGF1R-kin) 
A recombinant baculovirus was engineered to encode residues 956–1256 of 
IGF1R with the substitution C1207S using the pFastBacHT B plasmid (Life 
Technologies, Carlsbad, California). Sf9 cells at a concentration of 2 × 106 cells/ml were 
infected with this P3 baculovirus and harvested 3 days post-infection. The purification 
protocol was based on a previously published procedure (Favelyukis, 2001). Cells were 
lysed by using a French pressure cell press in buffer containing 50 mM Tris pH 8, 50 mM 
NaCl, 0.2% Triton X-100, Benzonase nuclease (Sigma, St. Louis, Missouri), and protease 
inhibitor tab-lets (Roche, Germany). IGF1R-kin was isolated by immobilized metal 
affinity chromatography (IMAC), and the histidine-tag was removed by overnight 
incubation with TEV protease. Calf-intestinal phosphatase (CIP) (New England Biolabs, 
Ipswich, Massachusetts) was also included in the incubation to dephosphorylate the 
protein. The next day, protein was loaded onto a size-exclusion column (Superdex 75 
26/60) equilibrated in 10 mM Hepes pH 7.5, 150 mM NaCl, and 5 mM β-ME, and the 
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monomeric fractions pooled. Pooled fraction were then loaded onto a monoQ column 
(5/50 GL) equilibrated in 10 mM Hepes pH 7.5, 5 mM β-ME and eluted with a linear 
gradient of NaCl. Fractions corresponding to the unphosphorylated protein, as judged by 
Coommassie Brilliant Blue stained native gel, were pooled, concentrated, and flash 
frozen in 20% glycerol. Phosphorylated fractions were pooled, concentrated, and 
incubated with 10 mM ATP and 30 mM MgCl2, desalted, and then repurified on a mono 
Q column. Fractions corresponding to the fully phosphorylated IGF1R-kin, as judged by 
Coommassie stained native gel, were pooled, concentrated, and flash frozen in 20% 
glycerol. 
Expression and purification of the IGF1R juxtamembrane kinase region (IGF1R-jmk) 
IGF1R-jmk, residues 930–1256 of IGF1R with C1207S substitution, was 
expressed in Sf9 cells as described for IGF1R-kin. The purification protocol was based 
on a previously published method (Craddock, 2007). Cells were lysed using a French 
pressure cell in buffer containing 50 mM Tris pH 8.0, 1 M KCl, 10% glycerol, 0.2% 
Triton X-100, Benzonase, and protease inhibitor tablets. Clarified lysate was applied to 
an IMAC column (Biorad, Hercules, California) and eluted with imidazole. IGF1R-jmk 
was then incubated overnight with TEV and CIP to remove phosphorylation and the N-
terminal histidine tag and dialyzed into 10 mM Tris pH 8.0, 200 mM KCl, 10% glycerol, 
0.2% Triton-X100, 2.5 mM β-ME, 1 mM PMSF at 4°C. The cleavage reaction was 
reapplied to an IMAC column and the flow-through collected. The flow through was 
diluted to a final concentration of 50 mM KCl and applied to a HiTrap Q (GE 
Lifescience, Pittsburgh, Pennsylvania) column equilibrated in 10 mM Hepes pH 7.5, 
0.2% Triton X-100, and 5 mM β-ME and eluted with a linear gradient of KCl. Fractions 
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containing IGF1R-jmk were pooled, diluted to a final concentration of 50 mM KCl, and 
loaded onto a monoQ column equilibrated in the same buffer as for the HiTrap Q column. 
IGF1R-jmk was eluted with a gradient of KCl. Fractions containing unphosphorylated 
IGF1R-jmk were analyzed as described above, concentrated, and flash frozen in 20% 
glycerol. Phosphorylated IGF1R-jmk fractions were pooled, concentrated, and incubated 
with 10 mM ATP, 30 mM MgCl2, and 10% glycerol. The sample was then desalted and 
purified via monoQ to isolate the fully phosphorylated IGF1R-jmk, which was then 
concentrated and flash frozen as described previously. 
Expression and purification of the IGF1R intracellular region (IGF1R-icd)  
A recombinant baculovirus was engineered to encode the entire IGF1R 
intracellular region, residues 930–1337 with the substitution C1207S and a C-terminal 
SBP tag, using the pFastBacHT B plasmid (Life Technologies). Expression, lysis, IMAC, 
and cleavage were the same as for IGF1R-jmk. Histidine-tagged Yersinia enterocolitica 
phosphatase (YOP) was used for dephosphorylation. After cleavage, IGF1R-icd was 
loaded onto an IMAC column and the flow-through was collected. Untagged IGF1R-icd 
was then loaded onto a Streptactin HiTrap column (GE Lifescience) and eluted with 10 
mM Hepes pH 7.5, 150 mM KCl, 5 mM β-ME, and 2.5 mM desthiobiotin. This 
purification steps ensures that IGF1R-icd had an intact C-terminal tail. IGF1R-icd was 
then purified on a G75 size-exclusion column equilibrated in the same buffer lacking 
desthiobiotin. Monomeric IGF1R-icd was then pooled, diluted, and purified as described 
above to isolate unphosphorylated IGF1R-icd. To generate fully phosphorylated IGF1R-
icd, partially phosphorylated IGF1R-icd was incubated with 10 mM ATP, 30 mM 
MgCl2, 0.05% Triton X-100, and 10% glycerol for 4 hr at 4°C. This sample was then 
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desalted into 10 mM Tris pH 8, 150 mM NaCl, 0.05% Triton X-100, concentrated, 
supplemented with 20% glycerol and flash-frozen. 
Expression and purification of full-length IGF1R (IGF1R-fl) 
IGF1R-fl, residues 1–1337 with a C-terminal histidine tag, was stably expressed 
in HEK293 GnTi− (ATCC, Mannasas, Virginia) cells by Fugene transfection followed by 
FACS sorting. IGF1R-fl expressing cells were grown in a shaking incubator 
supplemented with 8% CO2 in Freestyle Medium (Invitrogen, Carlsbad, California) 
supplemented with 1% FBS and 2 mM Glutamine, pelleted, and lysed in a liquid nitrogen 
mill (Spex Sample Prep, Metuchen, New Jersey). Lysed cells were resuspended in 50 mm 
Tris pH 8.0, 100 mM NaCl, 5 mM EDTA, 1 mM PMSF, 10% glycerol, and 2% β-
octylglucoside for 1 hr at 4°C and spun at 200,000×g at 4°C for 1 hr. Clarified lysate was 
incubated with cyanogen bromide-resin (GE Healthcare) coupled to the monoclonal 
antibody 24–55 (Soos, 1992) for 1 hr. The resin was separated by centrifugation, washed 
sequentially in buffer containing 1 M NaCl, 0.5 M Urea, or 10 mM MgCl2. Protein was 
eluted with 25 mM Tris pH 8.0, 200 mM NaCl, 1 M MgCl2, 10% glycerol, and 2% β-
octylglucoside, buffer exchanged on a desalting column into 20 mM Tris pH 8.0, 100 
mM NaCl, 1 mM EDTA, 0.1 mM PMSF, 10% glycerol, and 2% β-octylglucoside, and 
loaded onto a monoQ column equilibrated in 10 mM Tris pH 8.0, 1 mM EDTA, 0.1 mM 
PMSF, 2.5% glycerol, and 0.03% Triton X-100. IGF1R-fl was eluted with 300 mM 
NaCl, and IGF1R-fl containing fractions pooled, concentrated in a Pierce 100 kDa 
molecular weight cut-off spin concentrator, supplemented with 20% glycerol, and flash 
frozen. To produce dephosphorylated IGF1R-fl, the above protocol was followed with 
the addition of YOP to the resuspension step. To produce phosphorylated protein, the 
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above protocol was followed with the addition of 30 mM MgCl2 and 10 mM ATP to the 
cell resuspension step. 
Expression and purification of IGF1 
A plasmid encoding an N-terminal histidine tagged version of IGF1 was 
transformed into BL21(DE3) Rosetta2 cells (EMD-Millipore, Billerica, Massachusetts). 
Cells were grown at 37°C in Terrific Broth to an OD600 of 0.4, induced with 1 mM 
IPTG, and harvested 2 hr after induction. Cells were lysed using a French pressure cell 
press in 20 mM Tris pH 8.0 and 6 M Urea. Clarified supernatants were loaded onto an 
IMAC column and eluted into 12.5 mM Tris pH 8.0, 3 M Urea, and 125 mM imidazole. 
Elution fractions containing IGF1 were pooled and dialyzed three times: first for 2 hr at 
room temperature against 20 mM Glycine pH 10.5, 15 mM DTT, and 2 M Urea, second 
for 18 hr against 20 mM Glycine pH 10.5, 3 mM DTT, 1 M Urea, 1 M NaCl, 0.5 μM 
CuCl2, and 20% Ethanol, and third for 2 hr at 4°C against 25 mM Tris pH 8, 200 mM 
NaCl. The sample was centrifuged to remove insoluble aggregates, and the supernatant 
applied to a G75 sizing column equilibrated in 5 mM Tris pH 8, 200 mM NaCl. Fractions 
containing monomeric IGF1 were pooled, concentrated, and flash frozen in 50% glycerol. 
Purification of the 24–55 anti-IGF1R antibody 
A hybridoma cell line expressing monoclonal antibody 24–55 (Soos, 1992) (a 
generous gift from K Siddle) was grown in a shaking incubator in hybridoma medium 
(Gibco, Carlsbad, California). Conditioned medium was applied to a Protein G column, 
and the antibody eluted with 100 mM Glycine pH 2.7 and neutralized with Tris pH 9.0. 
The 24–55 antibody was concentrated and dialyzed into 100 mM NaHCO3 and 500 mM 
NaCl and coupled to cyanogen bromide-resin according to manufacturer's directions. 
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Expression and purification of fluorescent proteins 
Plasmids encoding N-terminally hexa-histidine tagged EYFP, mCherry, or 
mTurquoise were trans-formed into Escherichia coli BL21(DE3) cells. Cultures were 
grown in Luria Broth at 37°C to OD600 ∼0.6, and the temperature dropped to 18°C for 
30 min. IPTG was added to a final concentration of 1 mM, and the culture was grown 
overnight (∼16 hr). Cells were harvested by centrifugation and lysed using a French 
pressure cell press. An IMAC column was loaded with clarified lysate, washed with 20 
mM imidazole, and eluted with 250 mM imidazole. Protein-containing fractions were 
pooled, dialyzed, concentrated, and flash frozen. To minimize photobleaching, all 
expression and purification steps were performed in the dark. The purity of the 
fluorescent proteins was >90% after the nickel column as judged by Coommassie 
Brilliant Blue stained SDS-PAGE. 
In vitro kinase assays 
Radiometric kinase assays to determine kinetic parameters were performed as 
described previously (Qiu, 2009). Reactions were performed in 25 μl of a buffer 
containing 50 mM HEPES pH 7.5, 50 mM NaCl, 10% Glycerol, 0.5 mM DTT, 0.2% 
Triton X-100, 10 mM MgCl2, 0.2 mg/ml ovalbumin, 0.1 mM Na3VO4, and either fixed 
or varying concentrations of ATP and Biotin-KKEEEEYMMMMG as the peptide 
substrate. A previously identified consensus sequence was used as the peptide substrate 
with an extra N-terminal lysine added to help with solubility (Songyang, 1995). 
Reactions were performed at 30°C and quenched by the addition of 10 μl of 100 mM 
EDTA. 10 μl of 20 mg/ml avidin (ThermoFisher, Waltham, Massachusetts) was added to 
the reactions and the mixture was transferred to a concentrator with a 30-kDa molecular 
	   11	  
weight cutoff (Pall, Port Washington, New Jersey). Samples were then washed three 
times in buffer containing 0.5 M NaCl and 0.5 M Na2HPO4, pH 8.3 and counted. 
Turnover of the limiting substrate was less than 10%. Reactions were performed in 
duplicate, and values were generally within 20%. Data were fit by non-linear least-
squares to using the Michaelis–Menten equation to obtain apparent Km and kcat values.  
In vitro autophosphorylation assays 
10 nM of purified IGF1R-fl was incubated with 2 mM ATP in the same buffer as 
the in vitro kinase assays either without or without 50 nM IGF1. Upon addition of ATP, 
the reactions were incubated at 30°C, and samples were removed at various time points 
and immediately quenched with 83 μM EDTA. Samples were separated by denaturing 
SDS-PAGE electrophoresis and transferred to PVDF membranes. Blots were probed with 
an anti-phosphotyrosine (pY) (4G10, EMD-Millipore) or anti-IGF1Rβ antibodies, 
scanned with a Typhoon Scanner (GE Lifesciences), and intensities quantified with 
ImageJ. For autophosphorylation of IGF1R-kin variants, the same assay was used except 
IGF1R proteins were at 1 μM and ATP at 1 mM. 
Cell-based IGF1R activity assays 
IGF1R cell-based assays were based on established procedures (Liu, 2012). 
HEK293 cells (ATCC) were maintained in adherent culture in DMEM:F12 supplemented 
with 5% FBS. HEK293 cells were chosen due to low background endogenous IGF1R as 
judged by Western blot and equal transfection efficiency of IGF1R wild-type and kinase-
inactive (D1205A/N) when compared with transient transfection of igf1r (−/−) mouse 
embryonic fibroblasts (a generous gift from R Baserga). HEK293 cells were plated in a 
six-well plate at 1 × 106 cells/well and transiently transfected with IGF1R expression 
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plasmids using polyethylenimine (PEI, linear MW 25,000; Polysciences, Inc., 
Warrington, Pennsylvania) at an optimized ratio of 1 μg DNA: 3 μg PEI. Variant IGF1R 
genes were subcloned into pSSX-F, a version of pSGHV0 modified to eliminate the 
growth hormone tag and add a C-terminal Flag tag (Leahy, 2000). After 18 hr, cells were 
washed three times with 2 ml Ham's F12 supplemented with 1 mg/ml BSA and incubated 
in this medium for 3 hr at 37°C to serum starve. In designated wells, 20 nM IGF1 was 
added and incubated for 30 min at 37°C. 
 For cross-linking assays and assays using truncated IGF1R variants, the wells 
were washed with ice-cold phosphate buffered saline and then lysed for 30 min at 4°C in 
250 μl of RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, and 0.1% SDS) supplemented with 1 mM activated Na3VO4, 1 mM 
PMSF, Benzonase nuclease (Sigma), and 10 mM iodoacetamide to prevent further 
disulphide-bond formation during lysis (Cao, 1992). Lysates were clarified and samples 
were separated by either denaturing reducing or non-reducing SDS-PAGE 
electrophoresis. Western blot analysis was performed using anti-IGF1Rβ (Santa Cruz 
Biotechnologies, Dallas, Texas) Western blots were developed using ECL2 (Thermo 
Scientific) and scanned using a Typhoon Imager. Bands corresponding to phosphorylated 
IGF1R from the 4G10 Western blot were quantified using ImageJ and normalized to 
receptor expression from quantified bands of the IGF1R-β Western blot for each 
experiment. 
 For autophosphorylation analysis, the wells were washed with ice-cold phosphate 
buffered saline and lysed in supplemented RIPA buffer lacking iodoacetamide. The cell 
suspension was clarified, and total protein concentration determined using the BCA 
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protein assay (Thermo Scientific-Pierce) to normalize cell lysates. For assays with 
truncated IGF1R proteins, Western blot analysis was performed on cell lysates using anti-
IGF1Rβ or anti-IGF1R phosphotyrosine 1135 (pY1135) (Cell Signaling Technology, 
Danvers, Massachusetts) antibodies. For assays with IGF1R-fl proteins with kinase 
clusters, single cysteine substitutions, or TM mutations immunoprecipitation was 
performed. Anti-Flag-M2 (Sigma) was added at 0.5 μg/ml to lysate followed by the 
addition of 20 μl Protein G Sepharose 4 Fast Flow (GE Healthcare). Lysates were then 
incubated overnight at 4°C. Beads were then washed three times with 1 ml of RIPA 
buffer supplemented with 1 mM activated Na3VO4. Beads were eluted by the addition of 
20 μl of 5× LDS loading buffer containing 10% fresh β-mercaptoethanol. Equal amounts 
of eluted proteins were analyzed as described for the cross-linking analysis but using both 
anti-pY and anti-IGF1Rβ antibodies. 
Two photon FRET microscopy on living cells 
 We employed two donor–acceptor FRET pairs for this study: mTurquoise-YFP 
and YFP-mCherry. We calculated the Förster radius for each pair to be 54.5 Å 
(mTurquoise-EYFP) and 53.1 Å (EYFP-mCherry), making them suitable for 
investigating conformational changes on the order of 30–90 Å. CHO cells were cultured 
in 35-mm collagen-coated glass bottomed dishes (MatTek Corporation, Ashland, 
Massachusetts) using phenol red-free DMEM-F12 supplemented with 5% FBS and 1 mM 
L-glutamine. Plasmids encoding the IGF1R extracellular and transmembrane regions 
fused after GGSGGS to mTurquoise (FRET donor) or EYFP (FRET acceptor) were co-
transfected using Fugene HD (Promega, Madison, Wisconsin) at a mass ratio of 3:1 
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(Fugene:DNA), according to the manufacturer's protocol. Transfection proceeded for 24 
hr at 37°C, 5% CO2. 
 We used the OptiMiS TruLine Spectral Scanning System (Aurora Spectral 
Technologies, Milwaukee, Wisconsin) for two-photon microscopy. A solid-state 
continuous wave laser pumped a mode-locked Ti:Sapphire laser (MaiTai DeepSee, 
Newport Corporation, Irvine, California) that generated near infra-red pulses in the 
wavelength range of 800–960 nm (λexc for mTurquoise = 800 nm; λexc for eYFP = 960 
nm). The beam was focused using a 63× objective (Nikon, Japan). Fluorescence emission 
from the sample chamber was projected through a transmission grating onto a cooled 
electron-multiplying charge-coupled device. The full spectral scans of all pixels in the 
viewing field (300 × 440 pixels) were completed in about 10 s. 
 Image acquisition and processing are based on the method described by (Raicu, 
2008). Prior to imaging, CHO cells were washed three times in 1× PBS to remove all 
traces of FBS, then serum starved in phenol red-free DMEM-F12 without FBS. After 5 hr 
of starvation, the media were changed a final time and the cells were imaged directly in 
the two-photon microscope. Individual donor and acceptor fluorescence spectra were 
collected from cells expressing either the donor- or acceptor-fused IGF1R alone. A single 
‘FRET’ scan (λexc, two photon = 800 nm) was acquired for each cell that coexpressed 
both EYFP and mTurquoise-fusion proteins. The full spectral emission profile was 
collected from 450–600 nm (1 nm resolution), and the FRET efficiency per pixel (EDAPP)  
was calculated using a Matlab program, according to the equations described (Raicu, 
2008)  
















where FD(RET) and FD(λex) equal the fluorescence emission of the donor in the presence 
and absence of resonance energy transfer, respectively. QA and QD are the quantum yields 
of the donor an acceptor fluorophore, and kDA and kAD are the maximum emission 
intensities of the donor in the presence of the acceptor, and the acceptor in the presence 
of the donor, respectively. The integrals of the individual emission spectra for the donor 
and acceptor are given by wD and wA. Representative pixels in each cell membrane were 
examined by eye to ensure a good fit to the FRET model. We calculated the Förster 
radius for the mTurquoise-EYFP donor–acceptor pair to be 54.5 Å using measured 
absorption and emission spectra from purified proteins (King, 2014). 
Confocal microscopy and quantitative imaging FRET 
CHO cells were cultured in DMEM-F12 supplemented with 5% FBS and 1 mM 
L-glutamine. Cells were seeded in 35-mm dishes at a density of 4 × 104 cells per well and 
grown for 24 hr at 37°C in 5% CO2, then transiently co-transfected with plasmids 
encoding IGF1R TM-EYFP (3 μg) and IGF1R TM-mCherry (6 μg) using the Fugene HD 
transfection reagent at a mass ratio of 3:1 (Fugene:DNA) according to the manufacturer's 
protocol. 
After 24 hr, cells were washed twice with 1 ml of 30% PBS, one minute per wash. 
1 ml of chloride salt vesiculation buffer (Del Piccolo, 2012) was added to each well, and 
the wells were incubated at 37°C, 5% CO2. Vesiculation buffer is composed of 200 mM 
NaCl, 5 mM KCl, 0.5 mM MgCl2, 0.75 mM CaCl2, and 100 mM bicine, pH 8.5. 
Vesiculation reached completion after about 12 hr, and the entire well supernatant was 
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transferred to 4-well chambered slides (Thermo Scientific, Nunc Lab-Tek II). The wells 
were allowed to equilibrate to room temperature before imaging.  
 Vesicle images were acquired using a Nikon C1 laser scanning confocal 
microscope equipped with a 60× water immersion objective. Three scans were taken for 
each vesicle: (i) a ‘donor’ scan (λexc = 488 nm, λem = 500–530 nm), (ii) an ‘acceptor’ 
scan (λexc = 543 nm, λem = 650 nm longpass), and (iii) a ‘FRET’ scan (λexc = 488 nm, 
λem = 565–615 nm). The donor and FRET scans used a 488 nm argon ion laser 
excitation source, while the acceptor scan used a 543 nm He-Ne laser. The image 
resolution was 512 × 512 pixels, with a pixel dwell time of 1.68 μs. The gains were set to 
7. All images were processed using a Matlab program developed in the Hristova 
laboratory. The program finds the boundary of each vesicle, verifies that the vesicle is 
present in all three scans, and fits the intensity profile across the membrane to a Gaussian 
function. The baseline is fitted with an error function. Details for the calculations of 
FRET efficiency are provided in the study by Chen et al. (2010a, 2010b). We calculated 
the intrinsic FRET efficiency as: 
€ 
Intrinsic FRET = (Eapp − Eproximity ) / xa  
where Eapp is the apparent FRET efficiency observed in each vesicle, Eproximity is the 
contribution of FRET from nonspecific interactions (King, 2014), and xa is a correction 
factor which accounts for varying ratios of donor and acceptor molecules within each 
vesicle. 
To determine fluorescent protein concentration in the vesicles, vesicle 
fluorescence intensities were normalized to standard solutions of mCherry and EYFP 
purified from E. coli BL21 cells using the formula (Chen, 2010a, 2010b): 










m  is the emission intensity of the donor per unit area of the membrane in the 
presence of RET, and 
€ 
ID,corr
m   is the donor emission intensity in the absence of RET (Chen, 
2010a, 2010b). Bleed through coefficients were calculated from confocal images of 
standard solutions of purified EYFP and mCherry. Using absorption and emission spectra 
of purified proteins, we calculated the Förster radius for the EYFP-mCherry donor–
acceptor pair to be 53.1 Å. 
Molecular dynamics simulations 
A simulation system was set up by tiling an equilibrated 15% POPS–85% POPC bilayer 
structure to a rectangular parallelepiped box of desired dimensions. The simulation box 
was filled with water molecules and 0.15 M NaCl. The POPS fraction was chosen to 
mimic the abundance of anionic lipids in mammalian plasma membrane (Zachowski, 
1993; van Meer, 2008), in which ∼10% of lipids are PS species, and few more percent 
are other anionic species, such as phosphoinositides. The bilayer was modeled with POPS 
only in the intracellular leaflet. The IGF1R TM helices were embedded in the  bilayer. 
The simulation box of two IGF1R TM helices for the two simulations of 12 µs and 34 µs 
is of 65 Å × 65 Å × 86 Å in dimensions and the simulation box of four IGF-1R 
transmembrane helices for the other two simulations of 24 µs and 36 µs is of 81 Å × 81 Å 
× 93 Å in dimensions. 
The systems were parameterized using the CHARMM36 forcefield for lipids and 
salt (Beglov and Roux, 1994), CHARMM TIP3P for water molecules (Neria, 1996), and 
the CHARMM22* forcefield (Mackerell, 1998, 2004; Piana, 2011) for protein. After 
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parameterization, the systems were energy minimized and were equilibrated in a 10 ns 
simulation with a NPT ensemble at 310 K temperature and 1 bar pressure. In the 
equilibration, 1 fs time step was used and harmonic positional restraints of a force 
constant of 1 kcal/mol/Å2 were initially applied to the protein backbone atoms. 
A production simulation was launched using the last frame of the equilibration 
simulation, with a NPT ensemble at 310 K and 1 bar using the Berendsen coupling 
scheme (Berendsen, 1984) with one temperature group and Nosé-Hoover thermostat 
(Hoover, 1985) with a time constant of 0.05 ps. All hydrogen-containing bonds were 
constrained using a recent implementation (Lippert, 2007) of the M-SHAKE algorithm 
(Krautler, 2001). Reversible reference system propagator algorithm 
(r-RESPA) integrator (Tuckerman and Berne, 1992) was used. Bonded, Van der Waals, 
and short-range electrostatic interactions were computed every 2 fs, while long-range 
electrostatic interactions were computed every 6 fs. All molecular dynamics simulations 
were performed using Anton, a special purpose supercomputer (Shaw, 2009) designed for 
such simulations. The short-range electrostatic interactions were calculated at a cutoff of 
9.48 Å, and the long-range electrostatic interactions were computed using Gaussian-split 
Ewald (Shan, 2005). 
Structural analysis 
Crystal lattice contacts for each crystal form analyzed were identified manually 
using the program PyMol and each kinase pair was individually defined. The Lsqkab 
program in CCP4 was used to superpose the kinase molecules of each pair on each kinase 
molecule in every other pair to identify any conserved interactions. Buried surface areas 
for each pair were calculated using Areaimol in CCP4. 
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Results 
Ligand binding disrupts interactions stabilizing IGF1R/IR TM separation 
To search for ligand-dependent conformational changes in the IR ECD, we 
compared the crystal structures of liganded and unliganded IR ECD fragments (Smith, 
2010; Menting, 2013). The reported dimer of the liganded IR fragment is mediated only 
by reciprocal interactions between L1 from one subunit and αCT from the other. As this 
dimer neither resembles the inverted ‘V’ conformation of the unliganded IR ECD nor is 
compatible with the inter-subunit disulfide bond between Fn1 domains, it is likely a 
nonphysiological artifact arising from the deletion of Fn2-ID-Fn3 domains and fusion of 
αCT to Fn1 (Menting, 2013). We therefore examined all IR interactions present in the 
crystal and identified an alternative dimer (Figure 1.4B), which had previously been 
noted as a part of a dimer of dimers (Menting, 2013), that is compatible with the disulfide 
bond between Fn1 domains (Schaffer and Ljungqvist, 1992) and preserves the inter-
subunit contacts between opposing L2-Fn1 domains (L2-Fn1:L2′-Fn1′) present at the 
apex of the inverted ‘V’ in the unliganded IR structure (Figure 1.4). Superposition L2-
Fn1:L2′-Fn1′ domains from the unliganded IR structure (Smith, 2010) and this 
symmetry-generated dimer of liganded IR (Menting, 2013) results in a root mean square 
deviation of 3.4 Å for 478 Cα atoms (Figure 1.4C and 1.4D). 
Using this superposition as a basis for comparing liganded and unliganded IR 
conformations reveals that the L1-CR domains rotate about a hinge between CR and L2 
(Figure 1.5A and 1.5B) when ligand binds. The position of this hinge is homologous to 
that of the hinge observed in the ECD of  EGFR when ligand binds, and most of the ∼50° 
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rotation can be ascribed to a rotation about the psi angle of Gly 306 (Burgess, 2003; 
Menting, 2013). The rigid-body rotation of the L1-CR domains repositions them further 
from the central axis of the IR dimer, exposes several residues on L1 that mediate Insulin 
binding, and disrupts an extensive interface between L1 and  Fn2′-3′ domains in 
unliganded IR (Figure 1.5C and 1.5D). (Hubbard, 2013; Menting, 2013). This inter-face 
fixes the relative positions of the Fn2–3 tandems in unliganded IR and stabilizes the 
∼120 Å separation of the Fn3 domains (and the immediately adjacent TM regions) 
observed in the absence of ligand. 
This observation led us to ask whether the TM separation enforced by the 
L1:Fn2′–3′ interface maintains the receptor in an inactive state in the absence of ligand. 
To test this possibility, we substituted several L1 residues that are both conserved 
between IGF1R and IR and occur at the L1:Fn2′–3′ interface with residues of opposite 
charge or increased size. These substitutions consistently resulted in poor processing 
and/or expression of IGF1R, however, which precluded analysis of their effects on 
IGF1R activation. We then analyzed an IGF1R variant lacking the entire L1 domain 
(IGF1R ΔL1) and found that it expressed well in HEK293 cells and was constitutively 
phosphorylated as judged by anti-phosphotyrosine Western blots (Figure 1.1C) 
demonstrating that the L1 domain is essential for maintaining the inactive state of IGF1R. 
The IGF1R extracellular region is autoinhibitory 
As deletion of the L1 domain results in constitutive activity of IGF1R, we next tested 
whether the role of the ECD might be to stabilize an inactive state in the absence of 
ligand as opposed to stabilizing the active state in the presence of ligand. We deleted 
most or all of the IGF1R ECD  and found that these truncated IGF1Rs (IGF1R Fn3-TM-
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icd and IGF1R TM-icd) are constitutively phosphorylated in the absence of ligand 
(Figure 1.1D).  A kinase-inactivating point mutation eliminated this phosphorylation, 
implicating autophosphorylation as the source of this signal.  The IGF1R ECD thus plays 
an active role in keeping the receptor off in the absence of ligand but is not needed to 
activate the truncated receptor. 
Release of IGF1R autoinhibition by ligand brings the TMs together 
Loss of either the L1 domain or the ECD eliminates the inter-subunit interaction 
between L1:Fn2′–3′ that fixes the separation of the TM regions. To examine if TM 
separation is altered in active receptors, we replaced the intracellular domain (ICD) of 
IGF1R with fluorescent donor or acceptor proteins (IGF1R ECD-TM-fp) and determined 
the FRET efficiency between co-transfected donor–acceptor pairs in the presence and 
absence of ligand (Figure 1.6A). We used spectrally resolved Förster resonance energy 
transfer (FRET) (Raicu, 2008) to calculate the FRET efficiency at the pixel level in 
transfected CHO cells, which ensures only proteins expressed at the cell membrane are 
included in the analysis. FRET efficiency increased twofold in the presence of ligand 
(Figure 1.6A). Assuming comparable if not random orientations of the fluorescent 
proteins in both states, these data indicate the C-termini of the TMs move closer together 
in the presence of ligand. A similar increase in FRET efficiency was observed in vesicles 
derived from CHO cells expressing IGF1R ECD-TM-fp in the presence and absence of 
ligand.  We also measured the FRET efficiency for IGF1R lacking the L1 domain 
(IGF1R ECDΔL1-TM-fp) and found that its FRET efficiency is similar to that of IGF1R 
ECD-TM-fp with bound ligand suggesting that the ligand bound state of IGF1R is similar 
to that of the receptor when the L1:Fn2′–3′ interface is disrupted (Figure 1.7) by 
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enforcing TM separation, introduction of flexible linkers between the ECD and TM 
regions should release this inhibition, and insertion of progressively longer linkers 
composed of glycine–serine containing repeats between 4 and 20 residues long indeed led 
to increasing levels of basal receptor activity (Figure 1.6B). 
Isolated IGF1R TMs dimerize 
The ligand-dependent decrease in distance between IGF1R TMs observed in 
FRET assays of IGF1R ECD-TM-fp led to the question of whether IGF1R TMs 
physically associate in the active state. Analysis of IR family TM sequences failed to 
identify any motifs known to mediate TM interactions, such as GXXXG (Russ and 
Engelman, 2000), but did identify an absolutely conserved proline (P911 in human 
IGF1R) (Figure 1.8A). To investigate the role of P911 in receptor activation, we 
performed cell based activity assays with IGF1R-fl bearing either a single P911L 
substitution or with additional substitutions to residues surrounding P911. These IGF1R 
variants became phosphorylated in a ligand-dependent manner suggesting P911 does not 
play a key role in mediating receptor activity, an outcome consistent with the results of 
earlier studies involving more dramatic manipulations of IR TM residues and suggesting 
lax constraints on TM sequence (Frattali, 1991; Yamada, 1992; Cheatham, 1993). 
To investigate the behavior of IGF1R TMs further, we performed molecular 
dynamics (MD) simulations of IGF1R TM monomers inserted into a 15% 
phosphatidylserine, 85% phosphatidylcholine bilayer. Four simulations extending 
between 12 μs and 36 μs were performed. In two of these simulations IGF1R TMs 
formed dimers in which the two TM helices cross each other opposite the conserved 
proline (Figure 1.8B). These dimers formed early in the simulations and were stable 
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throughout the rest of the runs. The IGF1R TMs also adopted several stable monomeric 
conformations in these simulations, occasionally with a sharp kink at P911 (Figure 1.8B). 
Experimental evidence that IGF1R TMs have an intrinsic propensity to dimerize 
in bilayers was obtained from quantitative imaging FRET (QI-FRET) experiments (Li, 
2008). Isolated IGF1R TMs were fused to C-terminal donor or acceptor fluorescent 
proteins (IGF1R TM-fp) and transiently transfected into CHO cells.  Vesicles containing 
variable amounts of expressed proteins were generated and FRET efficiency analyzed 
(Chen, 2010a; Del Piccolo, 2012).  FRET efficiency increased as a function of 
fluorescent protein concentration and exceeded both the theoretical levels of FRET 
expected to arise from random proximity (King, 2014) and the FRET efficiency of a 
control monomeric membrane protein (ErbB2 ECD-TM-fp) demonstrating an intrinsic 
propensity of IGF1R TMs to associate (Figure 1.8C). When examined on the surface of 
cells the FRET efficiency of IGF1R TM-fp overlapped with the FRET efficiency 
observed for IGF1R ECD-TM-fp in the presence of ligand suggesting similar TM 
separations in liganded IGF1R and isolated IGF1R TM dimers 
An intrinsic propensity of IGF1R TM and ICD regions to dimerize was also 
demonstrated by cysteine substitutions in constitutively active ECD-truncated forms of 
IGF1R (IGF1R TM-icd) (Figure 1.8D). The side chains of the extracellular membrane-
proximal residue H905 approach within 6 Å of one another in the MD dimer (Figure 
1.8B), and H905 or T898 were individually substituted with cysteine in IGF1R TM-icd 
variants. Western blots of reduced and non-reduced lysates from HEK293 cells 
expressing these proteins show that the majority of the H905C variant forms a disulfide-
linked dimer (Figure 1.8D). Lower amounts of dimerization were observed for the T898 
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variant in which the cysteines are farther away from the TM region (Figure 1.8D), and no 
disulfide crosslinking was observed for an equivalently truncated IGF1R without a 
cysteine substitution. These results demonstrate that, in the absence of the ECD, the 
IGF1R TM-icds come together in a manner consistent with the MD TM dimer. 
IGF1R TMs dimerize in the active, full-length receptor 
We next investigated whether juxtamembrane cysteines formed disulfide crosslinks when 
introduced into IGF1R-fl (Figure 1.9A). We could not directly analyze intra-dimer 
disulfide bond formation by introduced cysteines by analyzing migration on reducing and 
non-reducing SDS-PAGE owing to the native disulfide bonds linking α and β chains. To 
circumvent this issue, we substituted the cysteine residues that mediate the αβ disulfide 
with serine. These substitutions inhibited proper proteolytic processing of the receptor, 
however, obscuring differentiation of the new disulfide bond from native disulfide bonds. 
To our surprise, however, Western blots monitoring the phosphorylation of the IGF1R 
variants with the single substitutions of either T898C or H905C revealed high levels of 
phosphorylation in the absence of ligand (Figure 1.9A). An IGF1R-fl variant with a 
cysteine substitution immediately following the Fn3 domain and further away from the 
TM (Q895C) displayed only a modest increase in basal phosphorylation compared to 
wild-type (Figure 1.9A), perhaps owing to steric interference from Fn3 domains. 
The most likely explanation for the ligand-independent activity of IGF1R variants 
with single cysteine substitutions is that IGF1R samples the active conformation in the 
absence of ligand and becomes trapped in the active state by a disulfide bond. An intra-
dimer disulfide bond could not occur at these positions if the receptor was locked in the 
inactive ‘legs’ apart state by the L1:Fn2′–3′ interaction. This interaction must open 
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transiently for ligand to bind, however, and it appears this transient opening allows TM 
association. Alternatively, inter-dimer disulfides could form and activate the receptor. To 
distinguish these possibilities, we compared the migration of wild-type and IGF1R 
H905C on reducing and non-reducing SDS-PAGE. If the introduced cysteines form inter-
dimer disulfide bonds, some fraction of IGF1R H905C would migrate as a dimer of 
dimers or higher (molecular weight ≥ ∼640 kDa vs. ∼320 kDa for a dimer) on non-
reducing SDS-PAGE, and the ratio of H905C dimer to total monomer would decrease 
relative to wild-type IGF1R. Western blots show that this ratio remains the same for 
H905C and wild-type IGF1R, however, indicating the absence of appreciable inter-dimer 
disulfide formation by IGF1R H905C.  Sequence alignments show that H905, and the 
IGF1R juxtamembrane region in general, can be substituted with at least eleven different 
amino acids indicating the effects of cysteine at this site likely stem from its ability to 
form disulfide bonds. 
An intra-dimer disulfide between cysteines at position 905 would force TM 
association. When the H905C substitution was introduced into IGF1R ECD-TM-fp, the 
FRET efficiency of this variant in the absence of ligand matched that of native IGF1R 
ECD-TM-fp in the presence of ligand (Figure 1.9B). This result shows that the H905C 
substitution indeed leads to decreased TM separation, presumably owing to crosslinked 
juxtamembrane regions, and that this conformation is indistinguishable from that 
observed for liganded IGF1R ECD-TM-fp. 
Ligand binding does not stimulate the kinase activity of phosphorylated IGF1R 
To understand how changes in IGF1R ECD conformation are linked to receptor 
kinase activity, we next assessed the effects of ligand binding and autophosphorylation 
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on the kinase activity of IGF1R. We expressed full-length IGF1R (IGF1R-fl) in HEK293 
cells and purified it to near homogeneity for in vitro kinase assays.  To parse the 
contributions of specific regions to regulation of IGF1R activity, we expressed the 
isolated kinase domain (IGF1R-kin), the N-terminal juxtamembrane segment linked to 
the kinase domain (IGF1R-jmk), and the entire intracellular domain (IGF1R-icd) in Sf9 
cells and purified each fragment. Either fully phosphorylated or unphosphorylated (or 
minimally phosphorylated) versions of each form of IGF1R were prepared by incubation 
with ATP and Mg++ or phosphatase, respectively, during purification.   
The steady-state kinetic parameters of each form of IGF1R were determined using 
a direct, radiometric assay monitoring phosphotransfer from [γ-32P]ATP to a biotinylated 
peptide substrate.  Activity in this assay was linear with respect to both time and enzyme 
concentration for all forms of IGF1R.  Each intracellular IGF1R fragment showed barely 
detectable catalytic activity when unphosphorylated, which differed from the low but 
measurable activity of phosphatase-treated IGF1R-fl. Western blots indicated incomplete 
dephosphorylation of IGF1R-fl despite efforts to drive this reaction to completion, 
however, and residual autophosphorylation likely accounts for the elevated activity of 
IGF1R-fl relative to unphosphorylated IGF1R fragments. 
In contrast, robust activity was observed for all phosphorylated forms of IGF1R. 
Km,app values for both ATP and peptide ranged between 50 and 110 μM, and kcat values 
ranged between 98 and 749 min−1.  Addition of the juxtamembrane region (IGF1R-jmk) 
resulted in fourfold increase in kcat from that observed for IGF1R-kin, but addition of the 
C-tail (IGF1R-icd) had no effect on activity (Figure 1.10A). Notably, kcat differences of 
less than twofold were observed between phosphorylated forms of IGF1R-fl and either 
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IGF1R-jmk or IGF1R-icd indicating that the activities of these phosphoproteins are 
essentially equivalent. That is, the C- tail, ECD, and TMs do not contribute to the activity 
of phosphorylated IGF1R. Surprisingly, the kcat of phosphorylated IGF1R-fl is marginally 
less with ligand than without indicating that bound ligand also does not contribute to the 
activity of phosphorylated IGF1R-fl. 
Ligand binding stimulates IGF1R autophosphorylation 
Since the activity of phosphorylated IGF1R-fl is high and unaffected by ligand 
binding, we reasoned that autophosphorylation must be the step controlled by ligand-
dependent allostery. To test this idea, phosphatase-treated IGF1R-fl was incubated with 
ATP and Mg++ in the presence and absence of IGF1, and the rate of autophosphorylation 
monitored by Western blotting. The presence of IGF1 indeed led to a marked increase in 
the rate of autophosphorylation (Figure 1.10B). 
No evidence for specific intracellular domain interactions 
Interactions between kinase domains have proven essential for stabilizing the 
active state of EGFR (Zhang, 2006), and we wondered if specific interactions between 
kinase domains are coupled to active or inactive states in the IR family. To address this 
question, we analyzed lattice contacts in crystals of active and inactive IGF1R and IR 
kinases to determine if any contacts appear repeatedly or bear hallmarks of a 
physiological interaction. Several of nearly 300 unique contacts identified bury more than 
800 Å2 of surface area (Bahadur, 2004) but none appeared in multiple crystal forms or 
suggest a rationale for maintaining a stable active or inactive state (Figure 1.12). 
We next used mutagenesis and a cell-based activity assay to search for surfaces 
on the IGF1R kinase important for maintaining an inactive or active state. Six clusters of 
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3–9 alanine substitutions that blanket the IGF1R kinase surface were created (Figure 
1.13). Sites selected for substitution are solvent exposed, conserved between IGF1R and 
IR, and not part of the active site. Tagged versions of all six IGF1R variants were 
expressed on the surface of HEK293 cells (Figure 1.11A) and their levels of 
phosphorylation were assessed by Western blot after immunoprecipitation. In the absence 
of ligand, all variant IGF1Rs showed little or no phosphorylation, similar to wild-type 
IGF1R, and provide no evidence for an autoinhibitory interaction between kinases 
(Figure 1.11A). 
In contrast, two clusters of substitutions, one on the kinase N-lobe (C1) and one 
on the C-lobe (C4), resulted in loss of IGF1R phosphorylation in the presence of ligand 
(Figure 1.11A). Co-transfection of the two inactivating IGF1R N- and C-lobe variants did 
not restore activity indicating that they are unlikely to represent complementary surfaces 
of an asymmetric kinase dimer (Figure 1.11B). To ensure that the inactivating N- and C-
lobe mutations did not affect the intrinsic kinase activity of the receptor, IGF1R-kin 
proteins bearing these mutations were expressed and purified. Both variants retained 
autophosphorylation and substrate kinase activities but at lower levels than wild-type 
IGF1R-kin (Figure 1.14) and it cannot be ruled out that this decrease in intrinsic activity 
underlies the loss of ligand-dependent autophosphorylation observed in cells. 
 
Discussion 
We describe a molecular mechanism for IR/IGF1R activation in which ECD-
enforced separation of TMs maintains the receptor in an inhibited state. Ligand binding 
relieves this inhibition by disrupting the L1:Fn2′–3′ interaction that stabilizes TM 
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separation, freeing the TMs to associate and autophosphorylation of the kinase domains 
to proceed (Figure 1.15A). This model is based on a previously underappreciated dimer 
in the crystal structure of an Insulin bound IR ECD fragment, which provides a basis for 
comparing liganded and unliganded structures of the IR ECD. 
To validate this model, we present FRET and mutagenesis studies that 
demonstrate (i) a decrease in IGF1R TM separation when ligand binds, (ii) an intrinsic 
propensity of the IGF1R TM and TM-icd to dimerize, (iii) that the kinase is active in this 
associated state, consistent with the increased activity of the IGF1R ICD when fused to a 
dimeric partner (Baer, 2001), (iv) that the role of the ECD is primarily to inhibit this 
intrinsic kinase activity in the absence of ligand, rather than promote a specific active 
state, (v) that IGF1R TMs associate in an active form of the full-length receptor, and (vi) 
that IGF1R samples the active state even in the absence of ligand. Enzymatic studies of 
full-length IGF1R and IGF1R fragments further demonstrate no role for allostery in 
maintaining IGF1R activity once it is phosphorylated, indicating that the key step 
regulated by ligand binding is autophosphorylation. Although ligand binding has no 
effect on the intrinsic activity of phosphorylated IGF1R, the short half-life of IGF1R 
phosphorylation when phosphatases are present suggests the continued presence of ligand 
may be needed to maintain IGF1R activity (Kleiman, 2011). This efficiency of cellular 
phosphatases may also explain why transient sampling of the active state by IGF1R does 
not lead to constitutive activity. 
Previous models for IR activation have posited only modest changes in receptor 
conformation when ligand binds and that ‘twist’ rather than lateral movement of the Fn2–
3 domains is the activating signal or that the TM regions move from associated to apart 
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during IR activation (Ward, 2013; Lee, 2014). We show here that ligand binding to 
IGF1R leads to TM association. Thus the Fn2–3 domains must undergo a large 
movement upon ligand binding to accommodate the new position of the TMs. To model 
this movement, we appended the Fn2–3 tandems from the unliganded IR ECD structure 
to the structure of the IR ECD fragment bound to Insulin. The Fn2–3 tandems were then 
manually repositioned using only the constraints that the ligand bound position of these 
‘legs’ must be compatible with the TM dimer observed in MD simulations and that the 
residues on Fn2 that compose Site 2 contact ligand. Assuming the connection between 
Fn1 and Fn2 to be flexible (it buries ∼500 Å2 of surface area) and the Fn2–3 tandem to 
be rigid, we find it possible to place the Fn2–3 tandems so that Site 2 residues appose 
ligand and that the ECD C-termini are compatible with TM dimerization (Figure 1.15B–
D). 
We have modeled IR/IGF1R with two bound ligands (Figure 1.15D) but receptors 
with a single ligand bound may represent an important active state. Negative 
cooperativity implies that ligand binding at one site influences assembly of the second 
site. The most likely conduit of information between sites is through the αCTs, which are 
connected by an inter-subunit disulfide bond 8 residues from their N-termini. The αCTs 
are 30 Å farther apart in the liganded IR structure than in the unliganded IR structure 
(Smith, 2010; Menting, 2013). This increased separation is only possible because the 
inter-subunit disulfides that link the αCTs were deleted in the crystallized fragment of IR. 
In an intact receptor, the altered position of αCT following binding of one ligand would 
restrict the reach of the opposite αCT, likely hindering assembly of the second binding 
site and contributing to negative cooperativity. 
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The intrinsic propensity of the TMs to associate may also contribute to negative 
cooperativity. Disruption of the L1:Fn2′–3′ interaction by ligand binding removes a 
restraint on the relative position of the TMs that served as a barrier to TM association 
(Figure 1.5). Decreasing this barrier may shift the energetic balance between maintenance 
of the L1′:Fn2–3 interaction at the unliganded site and the intrinsic propensity of the TMs 
to associate and couple TM association to rearrangement of elements of the unliganded 
binding site.  This mechanism may underlie the restoration of negative cooperativity of 
soluble IR ECDs when their C-termini are artificially tethered (Hoyne, 2000). 
The results discussed so far implicate ECD-enforced TM separation as a key 
feature maintaining IGF1R and IR inactive states. The question then arises of how TM 
separation maintains the kinases in an inactive state. The simplest explanation is that 
spatial separation is sufficient to preclude one kinase from phosphorylating the other. The 
N-termini of subunits of an IGF1R kinase dimer captured in an apparent trans 
phosphorylation state are ∼50 Å apart (Wu, 2008), however, and the 27 residues 
separating each kinase domain from its TM could easily span the distance needed to 
reach the ~120 Å separation imposed by the ECD. The IGF1R intracellular 
juxtamembrane regions must thus adopt some structure in the inactive state to preclude 
autophosphorylation, but secondary structure prediction algorithms only identify a short 7 
amino-acid β strand in this region. Outside of three positively charged residues 
immediately following the TM, no conserved regions of positive charge com-parable to 
the region in EGFR thought to mediate interactions with the membrane are present (Jura, 
2009). Conversely, the fourfold enhancement of kinase activity when the juxtamembrane 
region is present implies some structure in this region in the active state. Attempts to 
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identify regions of the IGF1R kinase important for maintaining the inactive state by 
either mutagenesis or inspection of kinase crystal lattices for a repeated interaction 
proved unsuccessful, however. No IGF1R kinase surface mutations led to higher basal 
activity, and no repeated interactions or regions of positive charge are apparent in IGF1R 
kinase crystals that could mediate self interactions or interactions with the plasma 
membrane as has been proposed for EGFR (Arkhipov, 2013). 
In contrast, the absence of allosteric enhancement of the activity of 
phosphorylated IGF1R implies the absence of a stable interaction between kinase 
domains in the active state. Consistent with this conclusion, surface mutagenesis of the 
IGF1R kinase demonstrates the absence of an EGFR-like asymmetric kinase dimer. 
Absence of allostery in the active state may be a general feature of RTKs whose activity 
is enhanced by multiple activation loop phosphorylations, including FGFR, Met, 
VEGFR, Alk, MUSK, Kit, and their homologs (Lemmon and Schlessinger, 2010). 
Transient intermediate states may direct the order of tyrosines phosphorylated, as 
observed for FGFR (Lew, 2009), but once fully phosphorylated we suspect the activity of 
these kinases will also prove independent of allosteric stimulation. This behavior 
contrasts with that of EGFR, which relies on allostery via a kinase asymmetric dimer for 
activation rather than phosphorylation of the activation loop (Zhang, 2006). 
Although IGF1R ICDs do not appear to form a stable interaction in the active 
state, TM dimerization does appear to occur upon ligand binding. This observation is 
consistent with previous studies demonstrating a coupling between ligand binding and 
association of IR ECD C-termini as well as results with chimeric receptors. When the IR 
ECD is expressed in soluble form it binds with nearly 1000-fold lower affinity than full-
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length IR, but when the C-termini of the ECD are fused to either a leucine zipper (Hoyne, 
2000) or an immunoglobulin Fc region (Bass, 1996), high-affinity, native-like ligand 
binding is restored (Schaffer, 1994). TM dimerization is thus not only consistent with 
high-affinity ligand binding but promotes it. Furthermore, a chimeric receptor with an IR 
ECD and an EGFR TM and ICD can be activated by Insulin (Riedel, 1986). As EGFR 
activation involves TM dimerization (Endres, 2013), the Insulin-bound IR ECD is also 
compatible with TM dimerization. 
We present here a new molecular model for regulation of IGF1R and IR activity. 
The key feature of this model is maintenance of an inactive state by ECD-enforced 
separation of the TMs in the absence of ligand. Ligand binding releases this constraint, 
resulting in TM association and unleashing of the intrinsic propensity of the kinase 
regions to autophosphorylate and activate. This model is consistent with recent crystal 
structures of the IR ECD and suggests that some structure in the intracellular region 
precludes autophosphorylation in the unliganded state of the receptor. Conversely, 
enzymatic studies show that once phosphorylated and active, no structure outside of the 
kinase and juxtamembrane regions is needed to stimulate full kinase activity. This model 
provides a simple molecular context for understanding several features of IR/IGF1R 
activation and suggests directions for future study. It also suggests that chimeric proteins 
with IR or IGF1R ECDs may prove valuable for assessing the role of TM separation in 
other signaling systems or as ligand-dependent activity switches when fused, for 
example, to split enzymes. 
 




Figure 1.1. The extracellular domain of IGF1R autoinhibits IGF1R activity. (A, B) 
Schematic and cartoon representations of IGF1R. Numbering refers to human IGF1R 
excluding the signal sequence. Disulfide bonds are indicated by black diamonds. One αβ 
subunit is shown in outline and the other in color. (C) Cartoon of IGF1R full-length 
(IGF1R-fl) or an IGF1R fragment lacking the L1 domain (IGF1R ΔL1) (left). HEK293 
cells expressing either IGF1R-fl (FL) or IGF1R ΔL1 (ΔL1) were incubated with or 
without IGF1. IGF1R proteins were immunoprecipitated from normalized cell lysates and 
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levels of autophosphorylation or IGF1R expression detected by Western blot with anti-
phosphotyrosine (pY) or anti-IGF1Rβ antibodies (right). Molecular weight standards 
indicated to the left of each panel (D). Diagram of IGF1R variant lacking the ECD 
(IGF1R TM-icd) (left). Western blots probed with anti-pY1135, which recognizes a 
phosphotyrosine on the activation loop of the IGF1R kinase domain, and anti-IGF1Rβ of 
normalized lysates from cells expressing IGF1R-fl (FL) or IGF1R TM-icd (TM-icd), in 
the presence and absence of IGF1 (right). All panels are from the same blot.  
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Figure 1.2 Residues on IR important for ligand binding.  Worm diagram of the 
unliganded IR ECD with one αβ subunit colored white and the other orange. Residues 
implicated in forming the Site 1 binding surface are shown as cyan spheres and residues 
implicated in forming the Site 2 binding surface are shown in purple spheres (Mynarcik, 
1996; Whittaker, 2001; Whittaker and Whittaker, 2005; Whittaker, 2008). 
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Figure 1.3 Phosphorylation of the ICD. Cartoon of IGF1R-icd in the inactive or active, 
phosphorylated conformations. The activation loop is indicated by a purple line and 
phosphorylation sites as pink circles.  
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Figure 1.4 Conserved IR ECD dimer interaction. Surface representations of (A) the 
unliganded IR ECD dimer (PDB 3LOH; Smith, 2010) and (B) the IR ECD fragment 
bound to Insulin (PDB 3W14; Menting, 2013). Domains of one αβ subunit are colored in 
shades of orange, the other in shades of gray, and Insulin in light green. N-terminal 
domains are in darker shades. The conserved L2-Fn1:L2'-Fn1' interface is marked by a 
black box. Ribbon diagrams of these domain pairs are shown for the unliganded (C) and 
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liganded (D) IR ECD dimer. A cartoon of domains shown are included at the upper right 
of each structure. Dashed lines represent the missing Fn2-3 domain tandems. 
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Figure 1.5 Ligand-induced conformational change in the IR ECD.(A) Surface 
representation of the unliganded IR ECD (PDB 3LOH; Smith, 2010) oriented to show the 
L1:Fn2'-3' interface. The hinge between CR and L2 is indicated by a cyan circle. 
Cartoons of domains shown are to the upper right of each structure. (B) Surface 
representation of ligand-bound IR ECD fragment (PDB 3W14; Menting, 2013) in the 
same orientation as in A. The missing Fn2-3 domains are indicated by dashed lines. (C) 
Superposition of the ligand-bound IR structure (purple ribbon) onto the unliganded 
structure (orange and white ribbon) using the L2-Fn1 domain pairs. Insulin is displayed 
in light green. An arrow shows the direction of the relative movement of unsuperposed 
L1-CR domains about a hinge (cyan circle) between the CR and L2 domains. 
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Complementary halves of each receptor subunit were omitted for clarity. (D) A cartoon 
showing the movement of the L1-CR domain tandems. 
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Figure 1.6 The IGF1R ECD maintains TM separation. (A) Cartoon of the IGF1R 
ECD-TM-fp variant utilized in the live cell FRET assay (top). Frequency distribution of 
FRET efficiency values per membrane pixel of IGF1R ECD-TM-fp in the presence 
(green) or absence (white) of IGF1 (bottom). Data were fit to a normal distribution with 
peak values of 0.34 ± 0.09 and 0.21 ± 0.13 in the presence and absence of IGF1, 
respectively. (B) Cartoon of the IGF1R-fl and IGF1R variants with flexible linkers (top). 
Representative western blots probed with either anti-pY and anti-IGF1Rβ antibodies of 
immunoprecipitated, normalized cell lysates of untransfected cells (U) or cells transfected 
with IGF1R-fl (WT) or IGF1R variants with an additional 4 (+4), 9 (+9), 14 (+14), or   
20 (+20) glycine and serine residues per αβ chain (middle). Bar graph of average IGF1R 
phosphorylation normalized to total receptor concentration (±s.e.m.) from at least three 
separate experiments, except for +14 which was from 2. Results from cells incubated in 
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the absence of IGF1 are shown in white and in the presence of IGF1 shown in green 
(bottom).  
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Figure 1.7 The TMs associate in IGF1R ECD-ΔL1-TM-fp.  Cartoons of IGF1R ECD-
TM-fp and IGF1R ECD-ΔL1-TM-fp used in FRET assays (left). The intrinsic FRET of 
IGF1R ECD-ΔL1-TM-fp (blue) in vesicles plotted as a function of receptor concentration 
and fit to a horizontal line with a Y intercept of 0.36 ± 0.02 (right). Each data point 
represents the binned average of at least eight vesicles with error bars (±s.e.m. in both x 
and y). Shown for reference are the data and fits of IGF1R ECD-TM-fp without IGF1 
(white), with IGF1 (green), or the monomeric control ErbB2 ECD-TM-fp (purple). 
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Figure 1.8 IGF1R TMs associate.  (A) Sequence alignment of human IGF1R and IR 
extracellular juxtamembrane and TM regions. The position of the TM is indicated above 
the alignment. Bold lettering highlights residues targeted for substitution. H905 (red) and 
P911 (blue) are colored. (B) IGF1R TM monomer and dimer structures observed in MD 
simulations are shown in ribbon (white and pink). Shown in spheres are P911 (blue) and 
H905 (red). The lipid bilayer is in light gray. (C) The intrinsic FRET efficiency for 
IGF1R TM-fp plotted (pink) as a function of TM concentration. Also shown for reference 
are a monomeric control (ErbB2 ECD-TM-fp) in purple and the IGF1R ECD-TM-fp in 
the presence (green) or absence (white) of ligand. Each data point represents the binned 
average of at least eight vesicles (±s.e.m. in both x and y). For IGF1R TM-fp, the data 
	   46	  
were fit to a two state association model with a peak value of 0.38 ± 0.02. (D) Cartoon of 
IGF1R TM-icd with the positions of single-site cysteine mutations indicated in red (top). 
Anti-IGF1Rβ Western blots of lysates of HEK293 cells expressing either IGF1R-fl or 
IGF1R TM-icd fragments (WT, 898C or 905C) incubated with or without IGF1 and 
analyzed on non-reducing (middle) or reducing gels (bottom). 
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Figure 1.9 TMs associate in active IGF1R-fl.  (A) Cartoon of IGF1R-fl with cysteine 
substitutions (top). Western blots of immunoprecipitated normalized cell-lysates from 
untransfected cells (U) or cells transfected with IGF1R-fl (WT) or IGF1R-fl proteins with 
cysteine substitutions (895C, 898C, or 905C) incubated the presence or absence of IGF1 
(bottom). All panels are from the same blot. (B) Plot of the intrinsic FRET efficiency of 
IGF1R ECD-TM-fp with the H905C substitution (red) and fit to a horizontal line with a 
value of 0.38 ± 0.02. Each data point represents the binned average of at least eight 
vesicles (±s.e.m. in both x and y). For reference, the intrinsic FRET efficiencies and fits 
for IGF1R ECD-TM-fp with ligand (green) or without ligand (white) and the ErbB2 
ECD-TM-fp negative control (purple) are also shown 
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Figure 1.10 IGF1 stimulates autophosphorylation.  (A) Bar graphs of kcat (min−1) 
measurements are shown for phosphorylated forms of indicated IGF1R proteins. 
Diagrams of the specific fragments and the fold differences in activation are shown. (B) 
Anti-phosphotyrosine (pY) and anti-IGF1Rβ Western blots of IGF1R-fl as a function of 
time in the presence and absence of IGF1 (top). Quantification of band intensities in the 
presence (green circles) and absence (white circles) of IGF1 (bottom). 
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Figure 1.11 Surface mutations on the IGF1R kinase domain disrupt receptor 
activation. (A) Anti-pY and anti-IGF1Rβ Western blots of tagged IGF1R proteins 
immunoprecipitated from cells incubated in the presence or absence of IGF1. HEK293 
cells were transiently transfected with IGF1R-fl (WT), IGF1R bearing the kinase-
inactivating mutation D1105A (KD), IGF1R with clusters of surface mutations (C1-C6), 
or not transfected (U). Approximate locations of the mutated clusters indicated by a star 
on the kinase domain cartoons above each lane (top). Bar graphs showing mean receptor 
phosphorylation (±s.e.m.) from three independent experiments normalized to total 
receptor expression (for C3, only one experiment). White bars indicate cells incubated 
without IGF1 and green bars cells with IGF1 (bottom). (B) Western blots of IGF1R 
phosphorylation when C1 and C4 variants are co-transfected (top). Bar graph of receptor 
phosphorylation normalized to total receptor expression with the same coloring as in (A) 
(bottom).  
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Figure 1.12 Buried surface analysis of crystal lattice pairs of IR and IGF1R kinase 
domains.  A scatter plot of the buried surface area (Å2) of each crystal lattice pair of IR 
or IGF1R kinase domains. A dashed line (red) at 800 Å2 represents the minimal threshold 
of a biological interface (Bahadur, 2004) and a list of structures used in analysis and the 
numbering of the corresponding kinase pairs generated for each (Hubbard, 1994; 
Hubbard, 1997; Favelyukis, 2001; Parang, 2001; Pautsch, 2001; Till, 2001; Munshi, 
2002; Hu, 2003; Li, 2003; Munshi, 2003; Depetris, 2005; Li, 2005; Velaparthi, 2007; 
Mayer, 2008; Wu, 2008; Miller, 2009; Patnaik, 2009). 
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Figure 1.13: Surface analysis of IGF1R kinase domain.  The IGF1R kinase displayed 
in surface representation showing the location of each cluster colored according to the 
table of alanine substitutions made for each cluster (PDB 1P4O, Munshi, 2002). 
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Figure 1.14 Analysis of the autophosphorylation of IGF1R kinase clusters. 
Autophosphorylation of IGF1R-kin wild-type (WT), cluster 1 (C1) and cluster 4 (C4) as a 
function of time monitored by anti-pY Western-blot. All lanes shown are from the same 
blot. 
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Figure 1.15 Model of IGF1R activation. (A) Cartoon model of IR family activation. 
The IDs are shown as black lines in the ECDs, the disulfide linkages as black diamonds, 
phosphorylation as pink circles, activation loops as purple lines, ligand as green 
diamonds, and αCTs as cylinders. Surface representations and corresponding cartoon 
diagrams of (B) the ECD of unliganded-IR (PDB 3LOH; Smith, 2010), (C) insulin bound 
to the IR ECD fragment (PDB 3W14; Menting, 2013), or (D) a model of the entire IR 
ECD bound to two Insulin molecules. For each panel, one αβ subunit is colored white 
and the other orange, and Insulin green. Dashed lines outline the Fn2-3 domain tandems. 
The hinge point between F1 and Fn2-3 domains is indicated by black circles and cyan 
circles indicate the hinge point between CR and L2 domains. 
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Chapter 2. General and Specific Receptor tyrosine Kinase Signaling Mechanisms 
Revealed by Analysis of Chimeric EGFR and IR Family Receptors 
 
Abstract 
 Ligand-induced dimerization of receptor tyrosine kinases (RTKs) is a generally 
accepted mechanism of activation for all classes of RTKs except the Insulin Receptor 
(IR) family.  In contrast to all other RTK families, IR family members exist as preformed 
disulfide linked dimers on the cell surface.  Recent evidence suggests that the ectodomain 
(ECD) of IR, and that of its homolog the type 1 insulin-like growth factor receptor 
(IGF1R), maintains separation of subunit transmembrane regions in the absence of 
ligand.  Ligand binding releases this ectodomain autoinhibition and allows the 
transmembrane domains to come together and the intracellular kinase domains to 
transphosphorylate.  Parallels between the IR/IGF1R mechanism of activation and 
ligand-induced dimerization suggested that the IR/IGF1R ECDs may be able to regulate 
other families of RTKs, and we set out to understand how the IR/IGF1R activation 
mechanism relates to EGFR activation.  We find that the IR/IGF1R ECD fails to activate 
the kinase domain of EGFR in either IR-EGFR or IGF1R-EGFR chimeric receptors.  In 
contrast, the EGFR ECD is able to activate the IR kinase domain in an EGFR-IR fusion 
in an EGF-dependent fashion.  The IR and EGFR mechanisms of activation thus appear 
to share some but not all features. 
 
Introduction 
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 Receptor tyrosine kinases (RTKs) are a class of cell surface receptors defined by 
an extracellular domain (ECD), a single-pass transmembrane (TM) domain, and an 
intracellular region containing a tyrosine kinase domain (Reviewed in Lemmon and 
Schlessinger, 2010).  These receptors respond to various extracellular growth factor 
signals with enhanced intracellular kinase activity that in turn activates downstream 
signaling pathways involved in cell growth and differentiation.  There are fifty-eight 
RTKs in humans that assort into twenty classes based on homology.  Both topology and 
common mechanisms define the RTK family.  It is generally accepted that RTKs exist on 
the cell surface predominantly as monomers, likely in equilibrium with a small 
population of inactive preformed dimers, and binding of extracellular ligand induces 
receptor dimerization and activation.  Increasingly sophisticated methods of analyzing 
receptor structure and ligand binding suggest complex levels of regulation of RTK 
activity that complicate even the well-accepted notions of ligand-induced dimerization.   
Perhaps the most well studied, and often considered canonical, RTK is the 
Epidermal Growth Factor Receptor (EGFR) (Lemmon, 2014).  EGFR is one of four 
members of RTK Class I, which also includes HER2, HER3, and HER4.  Biochemical 
and structural studies of EGFR and other class I members are well advanced and thought 
in many instances to reflect general features of RTK behavior.  In the absence of ligand, 
EGFR is predominately a monomer and adopts a tethered conformation that blocks the 
EGFR dimerization interface (Figure 2.1).  The binding of EGF results in a 
conformational change whereby the dimerization interface is exposed, promoting 
receptor dimerization and kinase domain transphosphorylation.  Unique to EGFR is the 
formation of an intracellular, asymmetric dimer between kinases where the C-lobe of one 
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kinase domain contacts the N-lobe of the second kinase domain in the dimer and 
allosterically stimulates its kinase activity (Zhang, 2006).  Complicating the simplistic 
notion of an EGFR monomer dimerizing in the presence of ligand is experimental 
evidence for preformed, inactive EGFR dimers (Endres, 2013).  The nature of preformed 
dimers is not well understood although homologs of EGFR have begun to provide 
insight.  The Drosophila EGFR ectodomain has been crystallized as a dimer in both the 
presence and absence of ligand, revealing a distinct ECD dimer in the unliganded state 
(Alvarado, 2009; Alvarado, 2010).  More recently, a soluble construct of the ECD of Let-
23, the C. elegans EGFR homolog, was determined to be dimeric in solution (Freed, 
2015).  In cells, however, Let-23 maintains its kinase domain in an inactive state until the 
cognate ligand is added.  How ligand binding to a preformed dimer of human EGFR, or 
dimeric EGFR homolog, activates the receptor must include a conformational change 
whose nature is not well understood. 
 Further complicating the notion of ligand-induced dimerization is RTK Class II, 
the Insulin Receptor (IR) family, which in addition to IR includes the type 1 insulin-like 
growth factor receptor (IGF1R) and the insulin related receptor (IRR).  In contrast to all 
other RTK classes, IR, IGF1R, and IRR exist on the cell surface as preformed, disulfide-
linked dimers.  Ligand-induced dimerization cannot explain how IR is activated upon 
ligand binding.  Recent structural studies of IR have elucidated both snapshots of apo and 
ligand bound forms of portions of the IR extracellular domain (McKern, 2006; Menting, 
2013).  Furthermore, biochemical and biophysical studies of IGF1R have suggested that 
the role of the IGF1R ECD is autoinhibitory and serves to maintain transmembrane 
region separation in the absence of ligand (Kavran, 2014).  Ligand binding releases a 
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constraint in the ECD and allows the transmembrane regions to move closer together, 
resulting in kinase domain activation. 
This simple notion of transmembrane regions apart, receptor-off and 
transmembrane regions close together, receptor-on draws immediate parallels to ligand-
induced dimerization.  In the case of IR and IGF1R, ligand binding allows the 
transmembrane and intracellular regions to come close together and dimerize and the 
kinase domains to autophosphorylate.  Comparisons, then, between the mechanism of 
activation of IR and IGF1R with other RTK classes governed by ligand induced 
dimerization appeared worth investigating. 
The validity of this comparison is strengthened by widely accepted experiments 
involving chimeric IR and EGFR receptors.  Chimeric receptors with either the IR ECD 
fused to the EGFR TM  and intracellular domain (ICD) or the EGFR ECD and TM 
domain fused to the IR ICD were activated by the cognate ligand of the ECD (Riedel, 
1986; Riedel, 1989).  These experiments were performed in the early stages of RTK 
characterization, and the concept that these chimeric receptors are active has influenced 
mechanistic studies of RTKs for multiple decades. 
 Given recent advances in our knowledge of how IGF1 and insulin activate their 
receptors, we set out to replicate the IR-EGFR chimeric receptor experiment and extend 
the chimeric receptor approach to other RTK families.  Does the IR mechanism of 
activation extend to EGFR, as previously reported, and other RTK family members? Is 
the separation of transmembrane regions by IR sufficient to keep the EGFR kinase 
domains inactive? Is ligand-induced transmembrane association by the IR/IGF1R 
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ectodomains sufficient to activate the EGFR kinase?  Is the preformed dimer of IR really 
mechanistically distinct from the 19 other monomeric RTKs? 
   
Materials and Methods 
Buffers 
 Homemade RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% (v/v) NP40, 
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulfate was stored at 4°C 
for up to six months.  Phosphate buffered saline (PBS; 0.138 M sodium chloride, 0.0027 
M potassium chloride, pH 7.4).  PBS-T (PBS plus 1% (v/v) Tween 20).  
Reagents 
PureLink® HiPure Plasmid Midiprep Kit (Invitrogen by Life Technologies, 
K2100-05).  Polyethylenimine, PEI, linear MW 25,000 (Polysciences, Inc., 23966-2).  
PierceTM BCA Protein Assay (Life Technologies,  23225).  Protein G Sepharose 4 Fast 
Flow (GE Healthcare, 17-0618-01).  Dynabeads® Protein G (Novex by Life 
Technologies, 1003D).  Novex 4-20% Tris-Glycine Mini Protein Gels, 1.0mm, 15 well 
(Life Technologies, EC6025).  iBlot® Dry Blotting System and iBlot® Transfer Stacks, 
Nitrocellulose (Life Technologies, IB301001).  Thermo ScientificTM Pierce TM ECL 2 
Western Blotting Substrate (Fischer Scientific, 80197).    
Western Blots were placed on Apollo Plain Paper Copier Transparency Film (VPP100c) 
to image with the TyphoonTM FLA 9500 biomolecular imager (GE Healthcare Life 
Sciences).  Typhoon settings for ECL 2 were used(laser: 473 nm (Blue LD laser), filter: 
BPB1 (530DF20), PMT 400, and 100 μm resolution.     
Western Blot Protocol and Antibody Solutions 
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Nitrocellulose membranes were blocked for 30 minutes in blocking solution, 
PBS-T plus 3.3% (w/v) BSA prior to primary antibody.  Unless otherwise indicated, 
antibodies were diluted in blocking solution and membrane incubation with diluted 
antibodies proceeded for 1 hour at room temperature with gentle agitation.  After each 
antibody incubation, membranes were washed three times with PBS-T.  Working 
dilutions were kept for up to two weeks at 4°C.   
Antibodies are listed with name, clone identification number where applicable, 
vendor, catalog number and working dilution.  To detect pan phosphotyrosine, primary 
antibody used was anti-Phosphotyrosine, clone 4G10® (EMD Millipore, 05-321, 1:1000) 
and secondary antibody used was goat anti-mouse IgG2b-HRP (Santa Cruz 
Biotechnology, sc-2062, 1:3000).  To detect HA epitope tag, primary antibody was anti-
HA High Affinity (Roche, 11 867 423 001, 1:1000) and secondary antibody was goat 
anti-rat IgG-HRP (Santa Cruz Biotechnology, sc-2006, 1:2000).  To detect Myc epitope 
tag, primary antibody was c-Myc, 9E10 (Santa Cruz Biotechnology, sc-40) and 
secondary antibody was goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, sc-2006, 
1:1000).   
Expression vector design 
Regions of cDNA encoding all RTK variants were cloned into modifications of the 
vector pαH.  pαH is a vector derived from pHLSec (Aricescu, 2006) by substitution of an 
alternative multiple cloning site.  Modifications to pαH included signal sequence 
removal, addition of a common set of epitope tags, and addition of a panel of sequences 
of the IGF1R, EGFR and IR ECDs to facilitate easy cloning of chimeric receptors.  
Vector descriptions can be found in Table 2.1.   
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Full length human IGF-1R (NM_000875.4), IR, (NM_000208.2) and EGFR 
(NM_005228.3) cDNAs were used to generate full length and chimeric receptors.   
The following chimeric receptors were created to best reproduce previous IR/EGFR 
chimeras (Riedel, 1986; Riedel, 1989) and are also described in Table 2.2.  IG1R-EGFR 
is a fusion between the IGF1R ECD (amino acids 1-936) and the EGFR TM-ICD (643-
1210).  IR-EGFR is a fusion between the IR ECD (1-953) and the EGFR TM-ICD (643-
1210).  EGFR-IR is a fusion between the EGFR ECD-TM (1-668) and the IR ICD (979-
1382).  IGF1R-IR is a fusion between the IGF1R ECD-TM (1-929) and the IR ICD (979-
1382).  Where applicable, chimeric clones were spliced together at sites within 1-2 amino 
acids of the chimeric fusion protein previously assayed (Riedel, 1986; Riedel, 1989).  In 
the Riedel work, the EGFR transmembrane region was used in all chimeric receptors that 
contained EGFR.   
Additional IGF1R-RTK chimeric receptors studied utilized the IGF1R ECD or 
IGF1R ECD-TM fused to the TM-ICD or ICD or the RTK of interest.  An exhaustive list 
of all RTK clones can be found in Table 2.2.  Transmembrane boundaries for the RTK of 
interest were guided by domain annotation of mRNA and protein sequences from NCBI.  
In general, two amino acids were added prior to the transmembrane region for TM-ICD 
fusions or after the TM for ICD fusions. 
Transient transfection of HEK293 and CHO cells 
 Transient transfections followed methods previously described  (Kavran, 2014).  
Sterile, midiprepped DNA was used for cell-based assays.  In brief, CHO or HEK293 
cells were plated in six-well plates at 0.5 × 106 cells/well and transiently transfected with 
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expression plasmids using polyethylenimine at an optimized ratio of 1 μg DNA: 3 μg 
PEI.  Transient transfection proceeded for 18 hours.   
Generation of stably-transfected CHO cell lines 
 CHO stable cell lines were generated by transient co-transfection of the plasmid 
of interest with pCDNA3.1, a vector containing the Neomycin resistance gene.  
Transfection complexes containing PEI (30ug), RTK plasmid of interest (10ug) and 
pcDNA3.1 (0.1ug) were added to CHO cells seeded at 1x106 cells/well in a 150mm plate.  
After 24 hours, media was removed and replaced with fresh media containing 1mg/ml 
G418.  G418 selection proceeded for 7 days.  After 7 days, media containing G418 was 
changed every 2 days until colony formation was visible.  Colonies were isolated using 
cloning rings and split evenly between 2 wells of a 24 well plate.  One well was used to 
propagate the colony and the second was used to harvest cells and assay for expression.  
As nearly all clones picked expressed the construct of interest, the number of clones 
picked per construct was lowered from 16 for initial stables to 6.  Three different clones 
per construct were cryopreserved to represent a range of expression levels.     
Cell-based activity assays 
 Cell-based assays followed methods previously established to  assess IGF1R 
activity (Kavran, 2014).  For stable cell lines, cells were plated at least 2 hours prior to 
serum starvation.  For transient transfections, serum starvation began 18 hours after 
transfection.  Three hours of serum starvation was followed by 5 minute ligand 
stimulation at 37°C with 20 nM IGF1, 200 nM insulin, or 100 ng/ml EGF as indicated.  
Wells were washed with ice-cold phosphate buffered saline and then lysed for 30 min at 
4°C in 250 μl of RIPA buffer supplemented with 1 mM activated Na3VO4, 1 mM PMSF, 
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Benzonase nuclease (Sigma).  Total protein concentration of clarified lysates was 
determined using the BCA assay and lysates were normalized to lowest total protein 
content using RIPA buffer.  Immunoprecipitation was performed by adding normalized 
cell lysates to protein G dynabeads prequilibrated with anti-HA antibody.  To 
preequilibrate beads, 200 ng of anti-HA was mixed with 0.6 mg dynabeads in PBS plus 
0.01% Tween 20 by rotation for 30 minutes at room temperature.  Immunoprecipitations 
proceeded by rotating samples overnight at 4°C. The following day, beads were washed 
three times with 1 ml of RIPA buffer supplemented with 1 mM activated Na3VO4. 
Immunoprecipitates were eluted by addition of 30 μl of 2X SDS loading buffer 
containing 10% fresh β-mercaptoethanol to beads.  Equal amounts of eluted proteins 
were resolved using 4-20% Tris-Glycine gels and protein was transferred to 
nitrocellulose.  Blots were developed using both anti-pY and anti-myc or anti-HA.  Anti-
HA was used for detection only when anti-myc detection level was low.  Western blots 
were developed using ECL2 and chemifluorescent signal was determined by a scan with 
the Typhoon FLA 9500 biomolecular imager.  Band density of phosphorylated (4G10) 
and total (myc or HA) receptor was determined using ImageJ and receptor 
phosphorylation normalized for expression was compared between samples.  Care was 
taken to only quantify bands within the linear range for each antibody.  
 
Results 
Transient transfection of chimeric receptors results in high background phosphorylation 
and inactive IGF1R-EGFR chimeric receptors 
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 Previous cell based IGF1R activation assays (Kavran, 2014) utilized transient 
transfection of HEK293 cells.  Transiently transfected IGF1R in HEK293 cells has low 
basal phosphorylation and robustly responds to IGF1 stimulation (Figure 2.2, lanes 2 and 
3).  Initial attempts at chimeric receptor experiments reproduced this protocol with the 
intention of screening a large panel of IGF1R-RTK chimeric receptors.  However, this 
experimental approach yielded ambiguous results.  IGF1R-EGFR receptors, mimics of 
previously reported chimeric receptors, failed to show IGF1 induced stimulation as 
judged by anti-phosphotyrosine Western blots (Figure 2.2, lanes 4,5).  For all chimeric 
receptors tested, the only chimeric IGF1R-RTK receptor displaying a robust response to 
ligand was the IGF1R-IR chimera (Figure 2.2, lanes 6 and 7).   
Given that HEK293 cells have endogenous EGFR receptors and CHO cells lack 
detectable EGFR expression, transient transfection of CHO cells was tested with the 
same result as observed in HEK293 cells.  That is, IGF1R-EGFR chimeric receptors 
failed to activate.  This result was independent of whether the TM in the chimera was 
from IGF1R or EGFR or whether the ECD was IGF1R or IR.  High background 
phosphorylation of EGFR kinase domains, both in the full length, wild-type receptor and 
the chimeric receptor, as a result of transient transfection was observed and cause for 
concern, and stable cell lines experiments were pursued to avoid potential artifacts 
stemming from transient transfection. 
Stable cell transfections reveal unique patterns of chimeric receptor activation 
Stable CHO cell lines were generated for wild-type EGFR, IR, and IGF1R, and 
three different chimeric receptors EGFR(ECD-TM)-IR(ICD), IR(ECD)-EGFR(TM-ICD) 
and IGF1R(ECD-TM)-EGFR(ICD).  CHO cells lack endogenous EGFR, but stable 
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transfection of full length EGFR renders CHO cells responsive to EGF and robust EGFR 
phosphorylation is seen when EGF is added (Figure 2.3, lanes 4 to 6).  Stable 
transfectants of full length IR and IGF1R are responsive to insulin and IGF1, respectively 
(Figure 2.3, lanes 2 to 4 and 14 to16).  Chimeric receptors of IR-EGFR and IGF1R-
EGFR again failed to robustly respond to insulin or IGF1, respectively, as was observed 
in transient transfection experiments (Figure 2.3, lanes 7 to 9 and 19 to 21).  A faint band 
may be seen for phosphorylated EGFR kinase in lanes with insulin/IGF1 addition (lanes 
8 and 20); however, it is markedly less intense than stimulated wild type receptor.  
Whether this band is specific to the chimeric receptor but less intense will be further 
investigated.  Given endogenous IR/IGF1R receptors that respond to ligand in CHO cells, 
crosstalk between ligand stimulated IR/IGF1R receptors, either directly or indirectly, 
could be cause of this low level phosphorylation.  An IR/IGF1R small molecule kinase 
inhibitor will be used to test this hypothesis.  In contrast to transient transfection 
experiments, background phosphorylation of the EGFR kinase domain in both wild type 
and chimeric receptors was below detection limits, and the EGFR-IR chimera displayed 
strong activation when stimulated with EGF (Figure 2.3, lanes 10 to 12).  Given that 
CHO cells lack endogenous EGFR, we can rule out any signal from endogenous EGFR.  
The control chimeric receptor of IGF1R-IR did activate when IGF1 was added (Figure 
2.3, lanes 16 to 18); however, given background levels of endogenous IGF1R, we cannot 
determine whether this activation is direct or the result of phosphorylation via hybrid of 
endogenous IGF1R heterodimerized with stably transfected IGF1R-IR receptors.   
 While a slight glycosylation defect is seen in the proreceptor of the IR-EGFR 
chimera, it is not seen in the IGF1R-EGFR chimera.  Given a majority of the proreceptor 
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appears to be correctly processed for IR-EGFR, and the IGF1R-EGFR gives the same 
result, we do not believe glycosylation defects to be a cause for this negative chimera 
result.  We will confirm that the IR-EGFR is expressed on the cell surface using cell 
surface biotinylation.   
Discussion 
 We were admittedly surprised by our IR-EGFR and IGF1R-EGFR chimeric 
receptor results and pursued multiple cell lines and stable vs. transient expression to 
confirm this result.  For ease of discussion, we will refer to the IR-EGFR chimera but 
results were consistent with both IR-EGFR and IGF1R-EGFR.  Initial intentions to 
survey activation of more classes of RTK intracellular regions when fused to IGF1R 
extracellular regions were set aside owing to the irreproducibility of the reported 
activation of IR-EGFR chimera (Riedel, 1986; Riedel, 1989).  Given that our IR-EGFR 
chimera does signal, we are left to wonder what prevents this chimeric receptor from 
signaling when the inverse EGFR-IR chimera is responsive to EGF.   
The EGFR and IR classes of RTKs have multiple similarities, especially when 
relating to extracellular domain structure and ligand binding.  Both receptor families form 
dimers mediated solely by the receptor.  For IGF1R and IR, this is the constitutive state 
of the receptor.  For EGFR, ligand binding stimulates dimerization; however, the 
dimerization interface is made up solely of  receptor (and not ligand) surfaces.  In 
contrast, all other RTKs studied have fully ligand mediated dimers, or partial-ligand, 
partial-receptor mediated dimers.  Both IR and EGFR family receptors also display 
negative cooperativity.   ECD enforced TM association in the active state has been 
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proposed for both receptors based on FRET, mutagenesis and crosslinking studies, and 
liganded EGFR ECD crystal structures (Kavran, 2014; Lemmon, 2014) 
Divergence between EGFR and IR/IGF1R is found in mechanisms of kinase 
domain activation.  EGFR adopts an active, asymmetric dimer where the C-lobe of one 
kinase allosterically activates the N-lobe of the second kinase (Zhang, 2006).  Activation 
of the IGF1R kinase domain does not involve formation of the same asymmetric dimer as 
in EGFR (Kavran, 2014) and active IR/IGF1R kinases have recently been suggested to 
adopt a symmetric, dimeric active state allowing for active loop transphosphorylation 
(Cabail, 2015). 
 Why, then, can the dimerization of the EGFR ECD activate the IR kinase 
domain? To evaluate possible models, we will analyze our results piecewise.  First, the 
IR kinase domain is inactive when fused to the EGFR ECD-TM.  This result is easiest to 
model as the EGFR ECD is a monomer, and unpublished results from Patrick Byrne of 
our laboratory indicated that the EGFR ECD enforces TM separation in the absence of 
ligand.  In the absence of another kinase domain in proximity, the IR kinase domain 
cannot transphosphorylate.   
Second, the IR kinase domain in the EGFR-IR chimera activates in response to 
EGF.  Biochemical and structural studies of EGF bound EGFR dimers strongly supports 
transmembrane domains association in the active state  This proximity appears to be 
sufficient for the IR kinase in the EGFR-IR chimera to activate.  This observation 
suggests that the recently suggested IGF1R mechanism of activation, where TMs apart 
hold the IR kinase domain inactive but bringing the TMs together or in close proximity 
activates the IR kinase is not dependent on IR ECD specific features (Kavran, 2014). 
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 Conversely, why does EGFR kinase fail to activate in IR- or IGF1R-ECD 
chimeric fusion? First, the EGFR kinase domain is inactive when fused to the IR- or 
IGF1R- ECD and ligand is not present.   It is assumed that the IR and IGF1R ECDs in the 
chimeric receptors hold the EGFR TMs apart as they do in wild-type IR/IGF1R.  It is 
conceivable that the separation of the EGFR TMs by the IR ECD prevents the EGFR 
kinase from adopting the active asymmetric dimer state.  Given that evidence suggests 
wild type EGFR exists in some fraction of preformed, inactive dimers, it is probable that 
an inactive, dimeric state of the EGFR kinase exists, and this inactive state is favored in 
chimeric receptors of the IR or IGF1R ECD and the EGFR TM-ICD.   
Second, addition of insulin to the IR-EGFR chimera or IGF1 to the IGF1R-EGFR 
chimera fails to strongly activate the intracellular EGFR kinase.  This result is the most 
perplexing and requires experimental follow-up and further thought.  Ligand binding to 
the IR/IGF1R ECD results in a conformational change that brings the TMs in association.  
Whether this same change occurs in the chimeric receptor has not yet been determined.  
On one hand, if the conformational change is the same and TMs are brought together, this 
would suggest that the TM positioning in a liganded IR/IGF1R receptor is incompatible 
with formation of the active, asymmetric EGFR kinase domain dimer.  Given the reliance 
of EGFR activation on this asymmetric dimer, the inability to adopt this dimer would 
prevent receptor phosphorylation and rationalize our results.  To test whether the 
IR/IGF1R ECD conformational change occurs in the chimeric receptor, a mutation in the 
extracellular JM region, H905C, which traps the TMs together and activates the 
IR/IGF1R kinase domains, will be made and tested for activity. 
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Another possibility is that an interaction of the inactive kinases in the absence of 
ligand is energetically favorable, and the energy required to transition from inactive to 
active state is greater than that generated by the IGF1R or IR ECD upon ligand binding.  
Mutations in the EGFR kinase domain, such as L858R, that lead to ligand independent 
kinase activation, may aid in parsing these models when introduced into the chimeric 
receptor. 
Because we were unable to directly replicate previous chimeric receptor work, we 
question whether the relatively small (two- to four- fold) changes in autoradiography 
images with very high background may have been over interpreted (Riedel, 1989).  
Additionally, the antibodies they used to immunoprecipitate the receptors may have 
selectively immunoprecipitated ligand bound receptor.  Given the nature of the 
experiment and data presented in the earlier work, it is not possible to discern the total 
amount of protein in each post-immunoprecipitation kinase assay.  We have made every 
effort to reproduce the chimeric receptors used in previous reports and to use a cell line, 
CHO cells, which lacks at least one of the receptors of interest, EGFR.   
Future experiments include analysis of cell lysates to determine the activation 
state of downstream effector proteins.  Given that both the IGF1R/IR and EGFR 
pathways feed into the PI3K/MAPK pathway, it may be difficult do distinguish activation 
of the pathway by ligand stimulation of endogenous receptors vs. stably transfected 
clones.  We hope that a low background will allow us to confirm that insulin/IGF1 
addition to the IR- or IGF1R-EGFR chimeric receptors fails to activate downstream 
pathway components when compared with the EGFR full length stable cell line. 
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Mutational analysis of the IGF1R-EGFR chimeric receptor may also prove useful.  
As described above, the H905C mutation may answer whether the TMs do associate in 
the IR-EGFR and IGF1R-EGFR chimeras and if this TM association activates the EGFR 
kinase.  Additional information may come from decoupling the IGF1R ECD from the 
EGFR TM-ICD by insertion of flexible linkers of variable lengths, which activated the 
wild type IGF1R with as little as 5-10 amino acids inserted (Kavran, 2014).  Work with 
EGFR has also shown that adding residues to the extracellular juxtamembrane region 
decouples kinase activation from ECD inhibition (Chung, 2010).  If the specific TM 
conformation by the ligand bound IR/IGF1R-EGFR chimeric receptors inhibits the EGFR 
active state conformation, loosening the linkage may allow the TMs to assume a 
conformation compatible with the active, asymmetric dimer.   
What then to do with question of whether the IGF1R(ECD-TM)-RTK(ICD) 
chimeric receptors made with other RTK classes are responsive to IGF1? Results in 
transient transfections of HEK293 cells indicated that no other chimeras were active.  
First, stable cell lines, which provide the most reliable results, must be generated for both 
the chimeric and full length receptors of the RTKs of interest.  Creation of a small panel 
of these covering well known RTK classes such as Class III and Class IV where ligand 
binding is thought to bring membrane proximal extracellular domains in proximity is 
underway.  Chimeric receptors with ectodomains of IGF1R and EGFR should be assayed 
side by side.  While the IGF1R ectodomain may prove more specialized, given the 
EGFR-IR positive result, the monomer-dimer transition upon ligand binding to EGFR 
may be more likely to activate non-cognate RTK kinase domains.   
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Our data suggest that the manner in which IGF1 and insulin activate their 
receptors does not activate the EGFR kinase domain in chimeric receptors.  However, the 
manner in which EGFR activates its kinase domain does apparently activate the IR 
kinase.  This dichotomy between ECD identity and kinase activation suggests perhaps the 
insulin receptor family of RTKs, unique dimers amongst all RTK classes, have a 
specialized mechanism of activation that fails to cross to other RTK classes.   
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Figure 2.1 Epidermal growth factor activation.  In the absence of ligand, EGFR adopts 
a tethered confirmation.  Ligand binding to the extracellular domain of EGFR results in 
the adoption of an extended confirmation and subsequent dimerization.  The kinase 
domains of dimeric EGFR adopt a specific confirmation mediated by an asymmetric 
kinase dimer.  Figure reproduced from (Liu, 2012).   
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Table 2.1 RTK Expression Vectors.   A set of mammalian expression vectors were 
created from parent vector pαH.  Vector multiple cloning sites (MCS) were adapted to 
remove the signal sequence (V1), add C-terminal tandem myc-HA epitope tags (all), or 











as in MCS_B with the following insertion noted in bold:
as in MCS_B with the following insertion noted in bold:
as in MCS_B with the following insertion noted in bold:
as in MCS_C with the following insertion noted in bold:
as in MCS_B with the following insertion noted in bold:
RTK Vector Multiple Cloning Sites
Description
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Table 2.2 Panel of RTK Clones. For each RTK, a subset of clones was made to express 
full length, truncated and chimeric receptors with C-terminal myc-HA epitope tags.   
# RTK Name Expresses: # RTK Name Expresses:
1A EGFR FGFR2
1B EGFR(TM-ICD) 13B FGFR2(TM-ICD)
1C Cys-EGFR(TM-ICD) 13C Cys-FGFR2(TM-ICD)
1E IGF1R(ECD)-EGFR(TM-ICD) 13E IGF1R(ECD)-FGFR2(TM-ICD)
1F IGF1R(ECD-TM)-EGFR(ICD) 15A Ptk7
1G IGF1R(ECD-TM-iJM)-EGFR(KD-tail) 15B Ptk7(TM-ICD)
1H IR(ECD)-EGFR(TM-ICD) 15C Cys-Ptk7(TM-ICD)
2A ErbB2 15E IGF1R(ECD)-Ptk7(TM-ICD)
2B ErbB2(TM-ICD) 16A TrkA
2C Cys-ErbB2(TM-ICD) 16B TrkA(TM-ICD)
2E IGF1R(ECD)-ErbB2(TM-ICD) 16C Cys-TrkA(TM-ICD)
3A ErbB3 16E IGF1R(ECD)-TrkA(TM-ICD)
3B ErbB3(TM-ICD) 16F IGF1R(ECD-TM)-TrkA(ICD)
3C Cys-ErbB3(TM-ICD) 19A MuSK
3E IGF1R(ECD)-ErbB3(TM-ICD) 19B MuSK(TM-ICD)
5A IR 19C Cys-MuSK(TM-ICD)
5B IR(TM-ICD) 19E IGF1R(ECD)-MuSK(TM-ICD)
5C Cys-IR(TM-ICD) 19F IGF1R(ECD-TM)-MuSK(ICD)
5E IGF1R(ECD)-IR(TM-ICD) 20A Met
5F IGF1R(ECD-TM)-IR(ICD) 20B Met(TM-ICD)
5G IGF1R(ECD-TM-iJM)-IR(KD-tail) 20C Cys-Met(TM-ICD)
5H EGFR(ECD-TM)-IR(TM-ICD) 20E IGF1R(ECD)-Met(TM-ICD)
6A IGF1R 20F IGF1R(ECD-TM)-Met(ICD)
6B IGF1R(TM-ICD) 21A Ron
6C Cys-IGF1R(TM-ICD) 21B Ron(TM-ICD)
21C Cys-Ron(TM-ICD)
7A PDGFR 21E IGF1R(ECD)-Ron(TM-ICD)
7B PDGFR(TM-ICD) 21F IGF1R(ECD-TM)-Ron(ICD)
7C Cys-PDGFR(TM-ICD) 23A Tyro3
7E IGF1R(ECD)-PDGFR(TM-ICD) 23B Tyro3(TM-ICD)
10A Flt1 23C Cys-Tyro3(TM-ICD)
10B Flt1(TM-ICD) 23E IGF1R(ECD)-Tyro3(TM-ICD)
10C Cys-Flt1(TM-ICD) 27A EphA3
10E IGF1R(ECD)-Flt1(TM-ICD) 27B EphA3(TM-ICD)
11A VEGFR2 27C Cys-EphA3(TM-ICD)




























Figure 2.2 Transiently transfected IGF1R-EGFR chimeric receptors fail to activate. 
HEK293 cells transiently transfected with C-terminal myc-HA tagged IGF1Rfl (lanes 2, 
3), IGF1R(ECD)-EGFR(TM-ICD) (lanes 4, 5) and IGF1R(ECD-TM)-IR(ICD) were 
serum starved and then stimulated with 20nM IGF1 where indicated.  Normalized lysates 
were immunoprecipitated with an anti-HA antibody and immunoblotted with anti-
phosphotyrosine (4G10) and anti-myc (9E10) antibodies.  The black arrow denotes 
approximate position of proreceptor and the blue arrow denotes approximate position of 




Figure 2.3 IGF1R and EGFR activation in CHO cell stable cell lines. CHO stable 
cells for each construct indicated (from left to right, IR-full length, EGFR-full length, 
IR(ECD)-EGFR(TM-ICD), EGFR(ECD-TM)-IR(ICD), IGF1R-full length, IGF1R(ECD-
TM)-IR(ICD), IGF1R(ECD)-EGFR(TM-ICD), all containing C-terminal myc-HA 
epitope tags) were serum starved for three hours and then stimulated with indicated 
ligand for 5 minutes.  Normalized cell lysates were immunoprecipitated and 
immunoblotted with anti-phosphotyrosine (4G10) and anti-myc (9E10) antibodies. The 
black arrows denote approximate position of proreceptor and the blue arrows denote 
approximate position of the Beta subunit. 
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Chapter 3. Smoothened Structure and Function 
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Abstract 
A general aim of studies of signal transduction is to identify mediators of specific 
signals, order them into pathways, and understand the nature of interactions between 
individual components and how these interactions alter pathway behavior.  Despite years 
of intensive study and its central importance to animal development and human health, 
our understanding of the Hedgehog (Hh) signaling pathway remains riddled with gaps, 
question marks, assumptions, and poorly understood connections.  In particular, 
understanding how interactions between Hh and Patched (Ptc), a 12-pass integral 
membrane protein, lead to modulation of the function of Smoothened (Smo), a 7-pass 
integral membrane protein, has defied standard biochemical characterization.  Recent 
structural and biochemical characterizations of Smoothened domains have begun to 
unlock this riddle, however, and point towards improved cancer therapies.  Building on 
this evidence, we set out to express, purify, biochemically characterize and determine the 
structure of a constructs containing N-terminal cysteine rich domain (CRD) and 7-pass 
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Members of the Hedgehog (Hh) family of secreted signaling proteins are present 
in most metazoans and owe their name to the effects loss of Hh function has on 
Drosophila embryos, which lose their normal segmented pattern and develop a uniform 
coat of bristles reminiscent of the coats of hedgehogs (Nusslein-Volhard, 1980).  As 
presaged by this phenotype, Hh proteins mediate essential tissue patterning events during 
many stages of animal development (Ingham, 2011), and abnormal Hh function is 
associated with birth defects and cancer (Briscoe, 2013).  Hh proteins are also involved in 
tissue maintenance and wound repair in adult animals (Arwet, 2012).  Hh proteins 
achieve their patterning effects by functioning as classical morphogens (Heemsker, 
1994).  That is, Hh proteins form gradients of decreasing concentration from sites of 
secretion and induce concentration-dependent differentiation of distinct cell types 
(Gradilla, 2013; Ribes, 2009).  As befits a morphogen, Hh expression, release, diffusion, 
and signal reception are tightly regulated by multiple factors (Therond, 2012). 
 Classical and modern genetic techniques have identified several cell-surface 
proteins and glycans involved in receiving or modifying Hh signals (Ryan, 2012).  The 
core components of this process, conserved in all organisms known to have active Hh 
signaling, are Patched (Ptc) and Smoothened (Smo) (Figure 3.1) (Nakano, 1989; Stone, 
1996; Alcedo, 1996; van den Heuvel, 1996).  Ptc functions upstream of Smo and has 
been genetically and biochemically defined as a primary component of the Hh receptor 
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(Zheng, 2010; Fuse, 1999).  Ptc is a 12-pass integral membrane protein with distant 
homology to bacterial Resistance-Nodulation-Cell Division (RND) transporters (Taipale, 
2002; Tsent, 1999).  Transmembrane helices 2-6 of Ptc are also homologous to sterol-
sensing domains (SSDs), which are found in diverse integral membrane proteins and 
regulate activity in response to levels of free cellular sterols (Kuwabara, 2002).  Smo is a 
member of the Frizzled family (class F) of G-protein coupled receptors (GPCRs) (Ayer, 
2010), and contains an N-terminal, ~14kDa extracellular Cysteine-Rich Domain (CRD) 
connected via a linker to 7 membrane-spanning helices (7TM) and an extended (~200 
amino acids, human; ~450 amino acids, Drosophila) C-terminal tail.   
 Hh signaling responses are modulated by additional cell-surface components 
including CDO, BOC, Gas1, Hedgehog-interacting Protein, and Glypicans in vertebrates 
and Ihog, BOI, and the glypican Dally-like Protein in flies (Beachy, 2010; Yao, 2006; 
McLellan, 2006; McLellan, 2008, Bosanac, 2009; Bishop, 2009; Williams, 2010; Kim, 
2011; Izzi, 2011; Allen, 2011).  These factors either lack intracellular regions owing to 
glycophosphatidlyinositol anchors (Gas1, Glypicans) or have intracellular regions that are 
not implicated in Hh signaling and do not appear to transmit Hh signals across the cell 
membrane directly (Zheng, 2010).  Instead, transmission of Hh signals across the 
membrane appears to be mediated by Smo, the most downstream cell-surface component 
of the Hh signaling pathway.  Consistent with this role, the cytoplasmic tail of Smo 
becomes heavily phosphorylated and likely changes disposition when the Hh pathway is 
active (Zhang, 2004; Jia, 2004; Zhao, 2007).  These changes are coupled to intracellular 
signaling events that ultimately converge on members of the Gli family of transcription 
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factors, active forms of which translocate to the nucleus and upregulate expression of 
target genes (Hui, 2011).  
 Recent discovery of the importance of Ptc and Smo localization for normal Hh 
signaling has added additional complexity to Hh pathway regulation.  In vertebrates, 
Sonic Hh (Shh) and Hh pathway agonists result in movement of Smo from the plasma 
membrane to the primary cilium, a nonmotile flagellar-like organelle present on most 
cells, and dispersal of Ptc from its previous localization at the base of the primary cilium 
(Rohatgi, 2007).  Although movement of Smo to the primary cilium appears essential for 
normal Hh signaling in vertebrates (Haungfu, 2003), this movement is neither sufficient 
for signaling (Rohatgi, 2009) nor conserved in flies (Denef, 2000), and a core signaling 
capacity that is independent of ciliary localization must be present in Smo.  This 
minireview will focus on recent advances in structural and biochemical characterization 
of Smo, and readers are encouraged to consult other sources for background on additional 
Hh pathway components. 
Patched and Smoothened 
In unstimulated Hh-responsive cells Ptc functions upstream of Smo to inhibit its 
activity (Ingham, 2011).  Hh triggers signaling responses by interacting with Ptc to 
relieve this inhibition, but both how Ptc inhibits Smo and how Hh relieves this inhibition 
remain unclear.  As a small amount of Ptc is sufficient to inhibit a large stoichiometric 
excess of Smo (Taipale, 2002), Ptc does not appear to inhibit Smo through a direct 
interaction.  Rather, the homology of Ptc to transporters and the ability of Smo activity to 
be modulated by small molecules have led to the widespread belief that Ptc controls Smo 
through transport of a small molecule intermediary (Taipale, 2002).  Indeed, the ability of 
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Smo to bind and be inhibited by the plant sterol cyclopamine led to the development of 
compounds targeting the cyclopamine binding site for the treatment of cancers with 
abnormally active Hh signaling (Cooper, 1998; Taipale, 2000).  As some Smo-binding 
compounds function as Hh pathway agonists, it has been tempting to speculate that an 
endogenous cyclopamine-like compound modulates Smo activity (Chen, 2002).  Indeed, 
the sterol vitamin D3 has been proposed to function as a Ptc-dependent inhibitor of Smo 
(Bijlsma, 2006), although this observation awaits confirmation. 
Smo: 7TM Region 
The absence of knowledge of the physiological factors responsible for Smo 
activation—or inhibition—has presented a frustrating barrier to understanding Hh 
pathway regulation, but several recent results have begun to clarify this issue.  Firstly, 
Stevens and colleagues have determined atomic-resolution crystal structures of the 7TM 
region of human Smo complexed with 5 different small molecules, including 
cyclopamine (Wang, 2013; Wang, 2014; Weierstall, 2014).  These landmark structures 
show that, despite sharing less than 10% sequence identity with class A GPCRs such as 
rhodopsin and the β2-adrenergic receptor (β2AR), the Smo TM regions adopt an overall 
conformation very similar to that of inactive class A GPCRs (Figure 3.2A) 
(Venkatakrishnan, 2013).  As discussed in more detail below (Xie, 1998), this structural 
homology couples with the observation that activating mutation in Smo occur at sites that 
appear to stabilize the inactive state of class A GPCRs to suggest that the 7TM region of 
Smo is likely to undergo GPCR-like conformational changes during its activity cycle 
(Venkatakrishnan, 2013).  Such a conformational cycle would also be consistent with the 
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ability of Smo to signal through G-proteins in certain circumstances (Riobo, 2006; 
Philipp, 2009; Polizio, 2011a; Polizio, 2011b; Shen, 2013; Carbe; 2014).   
 Although the overall fold of its 7TM bundle is conserved with other GPCRs, Smo 
has additional features including an extension of extracellular loops (ECLs).  All of the 
co-crystallized compounds bind Smo in a long narrow pocket formed by the ECL 
extensions and upper portions of the transmembrane domains (Figure 3.2) (Wang, 2013; 
Wang, 2014; Weierstall, 2014).  The drug-binding pocket is exposed to the extracellular 
space suggesting that drugs and any endogenous ligands access the pocket from the 
extracellular surface.  This extracellular accessibility contrasts with a class A GPCR lipid 
receptor where the extracellular loops form a closed cage and ligand is thought to access 
its binding site from within the membrane (Hanson, 2012). Although the CRD was 
deleted from the crystallized Smo 7TM domain, the majority of the residues of the 
extracellular linker between the CRD and the first TM domain are present and adopt an 
ordered structure.  Disulfide bonds both within the linker and between the linker and the 
second extracellular loop appear to stabilize the linker structure (Figure 3.2A), and 
disruption of these disulfides results in increased Smoothened activity (Carroll, 2012).  In 
addition, the extracellular linker interacts with the extended extracellular loop connecting 
TMs VI and VII (ECL3), which forms a cap over the drug-binding pocket.  This ordered 
linker region suggests that the CRD may be directly coupled to the 7TM region and 
influence its conformation. 
 The five compounds crystallized in the Smo binding pocket include an agonist 
(SAG1.5) and four antagonists (LY2940680, SANT1, ANTA XV, and cyclopamine) 
(Figure 3.4).  All ligands bind in the pocket with their long axes perpendicular to the 
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plane of the membrane but vary in their depth relative to the extracellular outlet (Figure 
3.2B).  At the extremes, cyclopamine interacts predominantly with the extracellular loops 
while another antagonist, SANT-1, binds deep within the pocket, which spans 28 Å from 
the top of cyclopamine to the bottom of SANT1.  Asp 473, a residue that when mutated 
to histidine confers resistance to the anti-cancer agent Vismodegib (GDC-0449) (Yauch, 
2009; Robarge, 2009), lines the drug-binding pocket but interacts differently with 
different antagonists and does not confer universal drug resistance (Wang, 2013).  Asp 
473 does not directly contact LY2940680, for example, and the D473H substitution does 
not affect the activity of LY2940680 (Bender, 2011).  The variable susceptibility of 
individual drugs to resistance mutations suggests that second generation drugs or 
combination therapies may prolong the time to development of resistance. 
 LY2940680, cyclopamine, Anta XV, and the agonist SAG1.5 contact the 
Smoothened extracellular loops lining the top of the ligand binding cavity, but SANT1 
binds more deeply in the pocket and only contacts ECL2, which is positioned within the 
7TM region.  In contrast to cyclopamine, which binds more tightly to Smo than to a 
constitutively active Smo variant bearing a single-site substitution (SmoM2), SANT1 
binds both Smo and SmoM2 with equal potency (Chen, 2002). How the position of 
SANT1 deep within the 7TM bundle correlates to its ability to bind both Smo and 
SmoM2, whose W535L substitution occurs at the base of TM VII, is not clear.   Also of 
interest are the variable effects Smo antagonists have on Smo localization.  SANT1, 
LY2940680, and cyclopamine all inhibit Smo function, but only cyclopamine promotes 
the translocation of a still-inactive Smo to the primary cilium indicating translocation and 
activation are separable functions. 
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The failure of Smo to adopt an active-like conformation when bound to the 
agonist SAG1.5 is curious but not unprecedented for agonist-bound GPCRs (Warne, 
2011).  Binding of an agonist to an apparently inactive state may reflect a low energetic 
barrier between active and inactive states, conformational flexibility of the active state 
(Nygaard, 2013), and/or the effects of truncation of Smo N- and C-terminal regions.  
SAG1.5 binds in the same region of the binding pocket as LY2940680, ANTA XV, and 
cyclopamine, and Smo with SAG1.5 bound displays only slight alterations in binding 
pocket residues.  Larger conformational changes associated with active state GPCRs, 
such as the movements of TMs VI and VII to accommodate G-protein binding, are not 
seen in the Smo-SAG1.5 structure.    Crystallization of an active state of Smo may 
require adding back the CRD or portions of the C-terminal tail or co-crystallization with 
active conformation specific nanobodies (Ring, 2013).   Interesting subtleties about the 
effects of these different drugs on the conformational equilibria of intact Smo and their 
relation to Smo function clearly remain to be worked out. 
Smoothened: Cysteine-Rich Domain 
 A second major insight into Smo regulation emerged when three groups 
independently showed that oxysterols, oxidized derivatives of cholesterol, bind 
specifically to the Smo CRD and activate the Hh signaling pathway (Myers, 2013; 
Nedelcu, 2013; Nachtergaele, 2013).  Oxysterol binding by the Smo CRD is functionally 
as well as physically separable from small molecule binding to the 7TM site as deletion 
of the Smo CRD results in loss of oxysterol activation of Smo but does not affect the 
function of agonists and antagonists that target the 7TM region (Myers, 2013).  It had 
previously been shown that oxysterols could modulate Hh signaling by affecting Smo 
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function (Corcoran 2006; Dwyer, 2007; Nachtergaele, 2012).  The site of oxysterol action 
was not characterized at that time, although oxysterols did not appear to compete with 
cyclopamine for binding to Smo (Nachtergaele, 2012).   
The new reports all show that 20(S)-hydroxycholesterol (20(S)-OHC) (Figure 
3.4B) activates Smo by binding to the CRD.  Additionally, the Rohatgi and Siebold 
groups were able to determine the crystal structure of the zebrafish Smo CRD (Figure 
3.3B) (Nachtergaele, 2013).  All groups mapped the site of sterol action on the CRD via 
mutagenesis and in silico modeling to a hydrophobic groove that is homologous to the 
site at which the palmitoyl group of Wnt binds to the Frizzled CRD (Figure 3.3A) 
(Myers, 2013; Nachtergaele, 2013; Janda, 2012), confirming an earlier prediction based 
on structural homology that this region of Smo and Frizzled CRDs would bind lipophilic 
molecules (Bazan, 2009).  Curiously, the Drosophila Smo CRD does not bind to 20(S)-
OHC (Myers, 2013), but it and human Smo CRD were recently shown to bind to the 
glucocorticoid budesonide (Figure 3.4B) suggesting that sterol binding by the Smo CRD 
may be a conserved feature of Hh signaling (Rana, 2013).  Glucocorticoids represent an 
interesting class of Smo modulators as both inhibitors and activators of the Hh pathway 
have been found with glucocorticoid scaffolds, and budesonide inhibits wt Smo, 
SmoD473H and SmoM2 equally well - ideal features for a Smo-targeting drug (Wang, 
2012). 
 Variable specificity for 20(S)-OHC among Smo CRDs is perhaps not surprising 
given that the absence of a cellular sterol hydroxlase known to produce it makes it 
unlikely to be an endogenous ligand (Meyers, 2013).  Assuming endogenous ligands for 
Smo CRDs exist, the question naturally arises of what that ligand is.  A survey of 
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oxysterols for Smo modulatory activity found that 7-keto-27-OHC and 7-keto-25-OHC, 
both metabolites of 7-ketocholesterol, are able to stimulate Hh signaling in a manner that 
depends on the presence of the CRD (Myers, 2013).  Compounds that bind the CRD and 
inhibit (azasterols, e.g 22-NHC) (Figure 3.4B) or partially agonize (20(R)-yne, 20-keto-
yne) Smo activity validates the Smo CRD as a potential drug target and raises the 
possibility that an endogenous ligand for the Smo CRD may be an inhibitor rather than an 
activator (Nedelcu, 2013; Nachtergaele, 2013).  More work is needed to identify and 
validate potential CRD ligands, but it seems likely that such ligands exist, and their 
discovery and characterization will take our understanding of Hh pathway regulation in 
new directions. 
 Two immediately exciting prospects stimulated by the discovery of a specific and 
functionally important sterol-binding site on the Smo CRD were that it might be route by 
which Ptc modulates Smo activity or rationalize why cholesterol depletion reduces Hh 
signaling (Cooper, 2003).  Defying Occam’s razor, however, oxysterol binding by the 
Smo CRD cannot fully account for either of these processes. Deletion of the CRD from 
Smo (ΔCRDSmo) alters but does not abolish Shh mediated pathway activation (Myers, 
2013; Nedelcu, 2013; Nachtergaele, 2013).  Although varying levels of responsiveness of 
ΔCRDSmo to Shh have been reported, this is likely due to varying tags and expression 
systems.   Rohatgi and colleagues showed that oxysterol binding mutants of Smo retain 
negative regulation by Ptc and respond to Shh (Nachtergaele, 2013).  Beachy and 
colleagues showed that ΔCRDSmo has higher basal activity, but this activity can be 
reduced by co-expression with Ptc and further enhanced by addition of Shh indicating 
that Ptc can exert its effects on Smo independent of the CRD (Myers, 2013).  Higher 
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basal activity and Shh responsiveness of ΔCRDSmo were also reduced by cyclodextrin 
depletion, which reduces wild-type Smo activity (Cooper, 2003), suggesting the CRD is 
also not essential for this process but rather that cholesterol within the cell membrane is 
needed for normal Smo function.  Indeed, a specific role for membrane-localized 
cholesterol in Smo modulation has been suggested (Myers, 2013)   although no ordered 
cholesterol molecules were identified in the Smo crystal structures.   Modulation of Smo 
activity independent of the CRD or cyclopamine-binding pocket is not unprecedented as 
Itraconazole (Figure 3.4C) acts on Smo at a site distinct from both the canonical 7TM 
pocket and the CRD to inhibit Hh pathway activity (Kim, 2013).   
Cholesterol binding to the 7TM region of GPCRs is also not unprecedented.  The 
structure of β2AR bound to cholesterol and the partial inverse agonist timolol led Stevens 
and colleagues to propose a cholesterol consensus motif (CCM) in class A GPCRs 
(Hanson, 2008).  The CCM comprises 3 residues predictive of cholesterol binding: an 
aromatic residue (W,Y) at position 4.50, a positively charged residue at or about position 
4.43 that interacts with the cholesterol hydroxyl group, and a hydrophobic residue at 
position 4.46.  The positions here refer to the Ballesteros-Weinstein numbering for 
GPCRs (Ballesteros, 1995), which allows cross comparison of topologically equivalent 
residues in GPCR TMs and was recently extended to class F GPCRs (Wang, 2013).  
Interestingly, Smo W3654.50 overlays well with β2AR W1584.50, which stacks against the 
sterol ring of cholesterol in the β2AR structure with cholesterol bound.  While Smo does 
not have a positively charged residue at position 4.43, Smo residue H3614.46 maps to the 
hydrophobic position 4.46 of the CCM.  A nitrogen on the imidazole ring of H3614.46 is 
within 3.6 Å of the cholesterol hydroxyl group from cholesterol bound β2AR structure 
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(Hanson, 2008).  Whether these highly conserved class F residues, W3654.50 and H3614.46, 
act as an alternative cholesterol-binding motif presents an intriguing possibility. 
Targeting Smoothened in the Clinic 
 Hh pathway activating mutations in the gene encoding Ptc, and less commonly 
the gene encoding Smo, are found in subsets of several cancers, most notably basal cell 
carcinoma (BCC) and pediatric medulloblastomas (Xie, 1998; Goodrich, 1997).  
Constitutively active mutants (CAMs) of Smo found in sporadic BCC (W535L7.55 
“SmoM2”) and more recently in meningiomas and ameloblastomas (W535L7.55, 
L412F5.51) are resistant to Vismodegib treatment (Xie, 1998; Sweeny, 2014; Brastianos, 
2013; Clark, 2013). Superscripts refer to B&W numbering.   W5357.55 is absolutely 
conserved in class F GPCRs and maps to the intracellular tip of TM VII, a region 
structurally homologous to the NPxxY motif in class A GPCRs (Barak, 1995; 
Rosenbaum, 2009).  W5357.55 overlays with the Y7.53 of the NPxxY motif, which 
undergoes rearrangement in inactive vs. active structures of class A GPCRs (Ring, 2013; 
Deupi, 2012; Kruse, 2013),  L4125.51 is highly conserved across class F GCPRs and also 
appears in a conformationally labile region of GPCRs.  In class A GPCRs, residue 5.51 is 
one of a group of conserved hydrophobic and aromatic residues (3.40, 5.51, 6.44, 6.48) 
thought to constitute a “transmission switch” that rearranges when agonist binds 
(Venkatakrishnan, 2013; Deupi, 2011).  Collectively, these CAMs bolster the notion Smo 
cycles through canonical GPCR inactive-active states.  
 Vismodegib is a Smo inhibitor that binds to the 7TM pocket (Figure 3.4) and has 
been approved for the treatment of advanced BCC.  Resistance to Vismodegib usually 
appears within a few months, however (Chang, 2012).  Cancers with active Hh signaling 
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are often driven by inactivating Ptc mutations, but resistance mutations often appear in 
Smo, the target of the drug.  The Vismodegib resistance mutation originally found in 
medulloblastoma, D473H (Yauch, 2009), disrupts Vismodegib binding to Smo but does 
not result in Smo activation or loss of Smo regulation by physiological levels of Ptc.  
Additional drug resistance mutations in Smo were found in a mouse model of 
medulloblastoma where treatment with NVP-LDE225, a Smo 7TM antagonist, led to 
resistance mutations in Smo that predominantly localize to the 7TM binding pocket and 
result in phenotypes similar to D473H (Buonamici, 2010).  Several unique Smo 
resistance mutations (W281L2.57, V321M3.32) were also recently found in BCC after 
treatment with Vismodegib (Brinkhuizen, 2014).  W281L2.57 localizes to the base of the 
7TM binding pocket within 3.7 Å of the base of the LY2940680 ligand.  V321M3.32 is 
further buried at the base of the binding pocket and 5.8 Å from SANT1 at its closest 
point.  It is not known whether these mutations function to disrupt binding of Vismodegib 
to Smo or to activate Smo, but its position in the Smo structure suggests that W281L is 
more likely to interfere with ligand binding than V321M.  Given the rapid resistance to 
drugs targeting the Smo 7TM pocket, antagonists that bind the Smo CRD hold out the 
hope that drugs targeting the CRD may prove more effective or less susceptible to 
resistance when used either alone or in combination with compounds targeting the Smo 
7TM pocket (Nedelcu, 2013; Nachtergaele, 2013).  
 Any discussion of the Smo 7TM and CRD regions naturally leads to questions 
concerning how these components interact and how their interplay affects the Smo C-
terminal tail. Little is known about the structure of the Smo C-tail alone or with the Smo 
7TM bundle, but its low complexity and high hydrophilicity suggest it doesn’t adopt a 
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rigid globular structure. The Smo C-tail is phosphorylated in response to pathway 
activation although the identities of the kinases responsible for phosphorylation differ 
between vertebrates and invertebrates Jia, 2004 ; Chen, 2004).  A conformational change 
of the Drosophila Smo C-tail has been proposed to stem from C-tail phosphorylation 
altering interactions between positively charged clusters of Arg residues and negatively 
charged clusters of Asp residues (Zhao, 2007), but the vertebrate Smo C-tail does not 
possess the Arg clusters.  A C-tail conformational change in vertebrates has also been 
proposed, however (Chen, 2011). 
Summary 
Multiple inputs—oxysterol binding to the CRD, small molecule binding to the 
7TM pocket, and sterols within the cell membrane—are all capable of modulating Smo 
activity and presumably conformation.  Sorting out what the endogenous inputs are, 
which of these inputs are important in specific instances, how multiple inputs are 
integrated, how best to exploit various ways of modulating Smo for anticancer therapies, 
and the role of Ptc in modulating these and perhaps other inputs present exciting 
challenges.  Recent results have helped clarify the nature and sites of these inputs, 
however, and provided a framework for understanding how each of the parts fit together 
to achieve remarkable biological results. 
The onset of biochemical characterization of the 7TM region and the CRD 
domain alone, including panels of inhibitory and activating small molecules for each 
domain stimulated efforts on our part to express, purify, characterize, and determine the 
three-dimensional structure of the CRD-7TM Smo.   
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Methods 
Expression of Smo in Sf9 Cells  
 Smo variants for expression were designed and initial baculovirus directing their 
expression were generated by Ben Myers.  The two main constructs discussed are 7TM 
Smo, which is identical to the construct crystallized in the Stevens lab (Wang, 2013).  
Abbreviated in this work as 7TM Smo, the construct used was bRIL-hSmo-ΔCRD-ΔCT.  
The apocytochrome b562RIL was fused to the N-terminus of the CRD domain.  N-terminal 
affinity tags, a flag epitope followed by a 6X His sequence, were separated from bRIL by 
a TEV protease recognition site.  The primary CRD-7TM Smo construct used in protein 
purification and crystallization attempts was bRIL-mSmo-ΔCT.  The placement of bRIL 
and affinity tags was the same as in the 7TM Smo constructs.  Further manipulations of 
the CRD-7TM Smo variants involved removal of bRIL from the N-terminus and insertion 
of T4 lysozyme (T4L0 at intracellular loop 3.  Expression methods were identical for all 
variants,.  Baculovirus at an MOI of 5 was used to infect Sf9 cells for 72 hours.  Sf9 cells 
were harvested and flash frozen prior to protein purification. 
Purification of mSmo constructs 
 Protein purification followed methods described in (Wang, 2013) and illustrated 
in Figure 3.5.  In brief, isolated membranes were washed three times and resuspended by 
dounce homogenization.  Resuspended membranes were solubilized in 
1%DDM/0.2%Cholesterol Hemisuccinate (CHS).  TALON resin was used for initial 
protein capture and desalted TALON elution fractions were incubated with TEV protease 
for tag removal.  Reincubation with Nickel NTA resin was used to remove His-tagged 
TEV protease and proteolyzed tags.  Flow through from the Nickel NTA resin was 
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concentrated to 50 mg/ml for crystallization attempts.  A portion of this flow through was 
used for analytical SEC on a Superose 6 column pre-equilibrated with 0.03%DDM, 
0.006% CHS to assess protein monodispersity.  For protein intended for use in 
crystallization trays, modulators (i.e. Smo agonists and/or antagonists likely to stabilize 
active or inactive states of Smo) were added at the point of solubilization and maintained 
throughout protein purification.  For protein intended for thermal denaturation analysis, 
modulators were absent during prep and added prior to denaturation assay. 
Thermal denaturation of mSmo variants 
 Thermal denaturation assays were performed using CPM (N-[4-(7-diethylamino-
4-methyl-3-coumarinyl)phenyl]maleimide)  dye, a thiol-specific fluorochrome  from 
Invitrogen. A 1:40 dilution of a 4 mg/ml solution of CPM dye (Invitrogen) in DMSO was 
incubated for 5 min at room temperature, protected from light.  20 μg of Smo was diluted 
to a final volume of 290 μL.  After 5 min at room temperature, 10 μL of dilute dye was 
added to the Smo sample, which was mixed and transferred to a quartz fluorometer 
cuvette. The cuvette was transferred to a Fluorolog-3 spectrofluorometer (Horiba Jobin 
Yvon) equipped with a Peltier sample cooler (F-3004) and heated at a rate of 2°C/min. 
Emission at 463 nm was monitored with an excitation wavelength of 387 nm from 20°C 
to 80°C.  A melting temperature (Tm) was determined by fitting the curve to a sigmoidal 
Boltzmann equation.   
Lipidic cubic phase crystallization 
 Concentrated Smo protein was mixed with molten  90:10 monoolein:cholesterol 
at a ratio of 2:3 (w:w) using two Hamilton syringes connected by a syringe coupler.  
Mixing was performed by slowly mixing protein with lipid at a rate of 1 syringe stroke 
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per second.  Successful formation of the lipid cubic phase (LCP) was noted by transition 
of the mixture from non-uniform cloudiness to the optically transparent lipidic cubic 
phase.  The LCP mixture was then transferred to a 10 microliter Hamilton syringe and a 
repeating dispenser was used to aliquot 200 nanoliter drops onto glass sandwich 
crystallization plates.  One microliter of the precipitant solution was overlayed on the 
LCP drop.  Trays were sealed and incubated protected from light in a temperature 
controlled room.   
 
Results 
 7TM and CRD-7TM Smo proteins were expressed in Sf9 cells and purified using 
nickel affinity and size exclusion chromatography (SEC) (Figure 3.5, 3.6 and 3.7).  Both 
the 7TM and CRD-7TM variants were monodispersed, eluting immediately prior to the 
158kDa molecular weight standard (Figures 3.6B and 3.7B).  Accounting for the 
DDM/CHS micelle, Smo likely elutes as a dimer compared to molecular weight 
standards; however, further evaluation using MALS or alternative SEC columns may 
better resolve the oligomeric state of Smo.  The oligomeric state did not change with the 
addition of the CRD to the 7TM construct.  Maximum protein yields for 7TM Smo were 
300ug per liter of Sf9 cells.  Yields for the 7TM construct were consistent across protein 
preparations; however, CRD-7TM yields fluctuated with an average of 150ug per liter.  
CRD-7TM Smo had variable amounts of CRD cleavage from the 7TM domain over the 
course of protein purification.  This cleavage occurred differently when different 
modulators were added and is likely the source of inconsistent protein yields.  Changes in 
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media formulation and baculovirus multiplicity of infection (MOI) were used to optimize 
protein yields. 
 The effect of small molecule modulators of  CRD-7TM Smo were determined 
using thermal denaturation assays.  The apo CRD-7TM Smo had a Tm of 54.5°C and its 
thermal denaturation curve was cooperative (Figure 3.8).  The addition of a small 
molecule targeting either the Smo 7TM or Smo CRD domain did not affect the melting 
temperature when added individually.  However, when a modulator of the 7TM and a 
modulator of the CRD were added in combination, the Tm of CRD-7TM Smo increased 
by 2.5°C.  This change in Tm occurred whether 7TM modulator was an activator (Figure 
3.8A) or inhibitor (Figure 3.8B).  All crystal trays of CRD-7TM Smo included both a 
7TM and CRD modulator in efforts to maximize protein stability. 
 Purified 7TM Smo and CRD-7TM Smo purified proteins, at concentrations of 
50mg/ml, were used in lipidic cubic phase crystallization.  Although I was able to 
reproduce the 7TM Smo crystals in the presence of LY2940680 in a published 
crystallization condition (Wang, 2013), no other crystals were obtained.  Crystallization 
attempts included addition of a high affinity agonist, sSAG, with the 7TM Smo and a 
panel of 7TM agonists and antagonists along with 20(S)-OHC for the CRD-7TM Smo.  
The CRD-7TM Smo variant failed to give reasonable amounts of precipitate in any 
conditions tested.  Further manipulations to CRD-7TM Smo, including alternative 
placement of the bRIL domain and addition of T4L to intracellular loop 3 were tried; 
however, the removal of the bRIL domain from the N-terminus of the CRD-7TM Smo 
resulted in apparent instability of the protein throughout purification, and these additional 
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 Efforts to crystallize 7TM Smo in the active state and CRD-7TM Smo in the 
presence of modulators to both domains proved unsuccessful.  There are currently no 
structures of CRD-7TM Smo and while the 7TM Smo has been crystallized in the 
presence of one agonist, it failed to adopt a 7TM active state confirmation (Wang, 2014).  
Future efforts to capture a 7TM active state, if possible, may require the use of 
conformational specific antibodies/nanobodies.  The CRD-7TM Smo variant presents 
additional difficulties due to the lack of protein precipitation in all crystallization 
conditions tried, which members of the Kobilka lab at Stanford indicated is unfortunately 
a sign that crystallization is extremely unlikely.   
Nonetheless,  multiple strategies remain to be tried in future attempts to 
crystallize CRD-7TM Smo.  First, the CRD-7TM domain, with the removal of the bRIL 
domain from the N-terminus, was largely instable.  Screening of Smo homologs from 
different species may prove useful.  Indeed, the crystal structure of the CRD domain 
alone used the zebrafish Smo CRD.  Conformational specific nanobodies that prevent 
CRD cleavage from the 7TM domain could also prove useful.  Second, given the lack of 
precipitate in the most common lipidic cubic phase lipid, monoolein, additional LCP 
lipids may be tried.  Alternatively, the CRD-7TM Smo construct may not lend itself to 
LCP crystallization and more traditional hanging drop crystal trays with Smo in detergent 
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may prove more fruitful.  Finally, further analysis of modulators that stabilize the CRD-
7TM Smo domain beyond the 2.5°C increase seen here may be helpful.   
As our understanding of the biochemistry of the Smo CRD and of targeted Smo 
therapeutics increases, additional small molecules that stabilize Smo or aid in 
crystallization may be found.  Ultimately, the current lack of understanding of how Ptc 
regulates Smo presents the most compelling question concerning Smo biochemistry and 
structure.  The key to unlocking the CRD-7TM Smo structure may lie in the 
identification of the enigmatic regulator by which Ptc modulates Smo by function.	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Figure 3.1 Major transmembrane components of Hh signal reception and 
transduction.  Ptc (left) represses Smo (right) through an unknown, indirect mechanism.  
The interaction of Shh with Ptc relieves Ptc-mediated repression of Smo.  The SSD of Ptc 
(TM II-TM VI) is colored blue.  For Smo, the 8 cysteines mediating 4 disulfide bonds in 
the Smo ECLs are shown in green, the D473H Vismodegib resistance mutation in blue, 
the constitutively active W535L substitution in red, and pS/pT sites in the C-tail in 
orange. 
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Figure 3.2 Smo 7TM Region.  A. β2AR in complex with Carazolol (PDB: 2RH1) and 
Smo in complex with LY2940680 (PDB: 4JKV) colored by GPCR helix number.  Key 
Smo residues are shown in spheres (ECL disulfides, green; D473H, light blue; W535L, 
orange) B. All five Smo 7TM and ligand crystal structures (From left to right, PDB: 
4O9R, 4QIN, 4QIM, 4JKV, 4N4W). 
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Figure 3.3 Structure of class F GPCR CRDs. (A) The structure of the mouse Frizzled 
CRD 8 (PDB: 4F0A) shown with the palmitoleic acid moiety (red) from XWnt8.  The 
position of XWnt8 (structure not shown) is noted with a dashed black line.  (B) The 
structure of the zebrafish Smoothened CRD (PDB: 4C79) with 20(S)-OHC binding 
residues shown in red. 
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Figure 3.4 Smoothened-interacting small molecules.  (A) 7TM targeting small 
molecules.  (B) CRD targeting small molecules. C. Other Smo targeting small molecules.  




Figure 3.5 Purification of CRD-containing Smo variants. All Smo variants were 
purified from baculovirus infected Sf9 cells using nickel affinity chromatography 
followed by tag removal and size exclusion chromatography.   
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Figure 3.6 Purification of mSmo-ΔCRD-ΔCT (A) Purified 7TM Smo is shown on a 
Coomassie Brilliant Blue stained SDS-PAGE gel.  (B) 7TM Smo is monodisperse on a 




Figure 3.7 Purification of CRD-mSmo-ΔCT (A) Purified CRD-7TM Smo is shown on 
a Coomassie stained SDS-PAGE gel.  (B) CRD-7TM Smo is monodisperse on a 
Superose 6 column equilibrated in buffer containing 0.03%DDM/0.006%CHS. 
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Figure 3.8 Thermal denaturation of purified Smo protein  Thermal denaturation 
curves of purified CRD-7TM Smo using a thiol specific dye (CPM) in the absence or 
presence of indicated activators or inhibitors.  Melting temperatures (Tm) were 
determined by fitting curves to the sigmoidal Boltzmann equation.  
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Chapter 4. Detergent-solubilized Patched Purified from Sf9 Cells Fails to Interact 
Strongly With Cognate Hedgehog or Ihog Homologs 
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Abstract 
Patched (Ptc) is a twelve-pass transmembrane protein that functions as a receptor 
for the Hedgehog (Hh) family of morphogens. In addition to Ptc, several accessory 
proteins including the CDO/Ihog family of co-receptors are necessary for proper Hh 
signaling. Structures of Hh proteins bound to members of the CDO/Ihog family are 
known, but the nature of the full Hh receptor complex is not well understood. We have 
expressed the Drosophila Patched and Mouse Patched-1 proteins in Sf9 cells and find 
that Sonic Hedgehog will bind to Mouse Patched-1 in isolated Sf9 cell membranes but 
that purified, detergent-solubilized Ptc proteins do not interact strongly with cognate Hh 
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and CDO/Ihog homologs.  These results may reflect a nonnative conformation of 
detergent-solubilized Ptc or that an additional factor or factors lost during purification are 
required for high-affinity Ptc binding to Hh.  
 
Introduction 
 The Hedgehog (Hh) signaling pathway mediates key tissue patterning events during 
animal development, and abnormal pathway activity is associated with several cancers 
(Johnson, ., 1996; Goodrich, 1997). Hh proteins are secreted morphogens that specify cell 
fates in neighboring tissues in a concentration-dependent manner (Riddle, Johnson, 
Laufer, & Tabin, 1993; Heemskerk & Dinardo, 1994). The twelve-pass transmembrane 
protein Patched (Ptc) has been identified as a key Hh receptor in genetic(Hidalg, 1990; 
Ingham, 1991; Forbes, 1993; Marigo, 1996) and cell-based binding studies (Stone, 1996; 
Fuse, 1999) In the absence of Hh, Ptc constitutively inhibits the activity of Smoothened 
(Smo) (Ingham, 1991; Taipale, 2002), a seven-pass transmembrane protein. The 
mechanism of this inhibition is unknown but does not appear to involve a direct 
interaction between Ptc and Smo (Taipale, 2002). In the presence of Hh, this inhibition is 
relieved and the pathway is activated. For recent reviews, see (Beachy, 2010; Ingham, 
2012; Briscoe & Thérond, 2013; Ryan & Chiang, 2012). 
 Many additional proteins modulate Hh pathway activity, but their presence and 
activity are not always conserved across phyla. For instance, Gas1 positively regulates 
Hh signaling in mammals (Allen, 2011), but no Gas1 homolog exists in the fruit fly. 
Hhip, a cell surface protein that acts as a negative regulator by binding and sequestering 
Hh proteins in vertebrates (Chuang & McMahon, 1999) also has no apparent ortholog in 
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the fly. The mammalian proteins CDO and BOC are orthologous to the fly proteins Ihog 
and Boi and each binds its cognate Hh protein, but the manner and co-factor dependence 
of Hh binding by fly and mammalian orthologs is not conserved (McLellan, 2008).  
 Despite the central importance of the Hh signaling pathway in animal development 
and the identification of many key pathway components, little is known about the 
molecular details connecting these components. Ptc is presumed to control Smo activity 
by transporting a small sterol-like molecule, a hypothesis based on an array of 
circumstantial evidence: the homology of Ptc to proton antiporters in the RND 
superfamily; the presence in Ptc of a sterol-sensing domain, which in other eukaryotic 
homologs is related to cholesterol trafficking; the indirect inhibition of Smo by Ptc, 
which suggests an intermediate (Taipale, 2002); and recent structural and biochemical 
studies of Smo showing that sterols bind Smo and modulate its activity (Wang, 2013; 
Nedelcu, 2013; Myers, 2013). Nevertheless, ligand transport by Ptc has not been 
conclusively demonstrated, nor has a physiological ligand for Smo been identified. More 
generally, how Hh proteins modulate the activity of Ptc is not known, and no functional 
assay for purified Ptc has been established.  
 A direct interaction between Hh and Ptc is clearly the simplest and most likely 
interpretation for high-affinity Hh binding to Ptc-expressing cells and Hh modulation of 
Ptc activity (Marigo, 1996; Fuse, 1999). Assays measuring binding to the cell surface 
leave open the possibility that other cellular factors could be involved, however. For 
example, most cell-based binding studies predated knowledge of the importance of 
accessory proteins Gas1, CDO/Ihog and BOC/Boi for mediating interactions between Hh 
and the cell surface. These proteins are essential for both fly (Zheng, 2010) and 
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mammalian Hh signaling (Allen, 2011; Izzi, 2011). Members of the CDO family of 
proteins bind Hh proteins directly with low micromolar affinities (McLellan, 2006; 
McLellan, 2008; Kavran, 2010), whereas the affinity of mammalian Sonic Hedgehog 
(Shh) for binding to the surface of Ptc-expressing cells is in the low nanomolar range 
(Marigo, 1996; Fuse, 1999). This difference in affinity, as well as the fact that high-
affinity cell-surface binding is dependent on the presence of Ptc, would seem to indicate 
that Ptc itself directly binds Shh but that the affinity for the binary Shh-Ptc interaction 
may be weaker than the affinity of Hh for Ptc-expressing cells. The role of the CDO/Ihog 
family of proteins appears to be to function as co-receptors that enhance binding affinity. 
In this case, a ternary complex between Ptc, Hh and members of the CDO/Ihog family 
may represent the initial signaling complex at the cell surface. Evidence for such ternary 
complexes has been found for Drosophila Ptc and Ihog (Zheng, Mann, Sever, & Beachy, 
2010), but the evidence in the mammalian pathway is contradictory. Although CDO, 
BOC or Gas1 appear to be required along with Ptc for normal signaling in mammals 
(Allen, 2011; Izzi, 2011), the addition of the soluble Hh-binding domain of CDO 
(CDOFn3) actually competes for ShhN binding to Ptc on the cell surface (McLellan, 
2008). This observation suggests that the binding surfaces for Ptc and CDO on ShhN may 
overlap. This binding competition has been rationalized with the positive role of both Ptc 
and CDO in Hh signaling by the observation that physiological Hh is found in 
multivalent particles (Chen, 2004), allowing simultaneous Ptc and CDO binding. 
Multivalency is not required for high-affinity binding of Shh to Ptc on cells, however, as 
monomeric ShhN expressed in E. coli binds Ptc-expressing cells with high affinity 
(Marigo, 1996; Fuse, 1999).  Hh proteins also bind sulfated glycosaminoglycans with 
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affinities that can be in the micromolar range, which also likely contributes to high-
affinity interactions with the cell surface. 
 A major barrier to understanding Ptc activity and the nature of its interactions with 
Hh pathway components has been the difficulty of isolating functional forms of Ptc or Ptc 
fragments. Most information on the reported molecular mechanisms and binding partners 
of Ptc has been obtained indirectly, using cell, tissue or whole animal-based studies. We 
therefore undertook to express and purify mouse and Drosophila Ptc proteins with intact 
transmembrane and extracellular regions for binding studies with Hh and other Hh 
pathway components.  Sonic Hedgehog will bind to mouse Ptc in isolated Sf9 cell 
membranes, but we surprisingly find that Ptc proteins extracted and purified in the 
presence of detergents do not interact with soluble, cognate Hh or CDO/Ihog homologs 




 All chemicals were purchased from Sigma unless otherwise noted. Detergents were 
purchased from Affymetrix and included n-dodecyl-β-D-maltopyranoside (DDM), n-do-
decylphosphocholine (fos-choline 12, FC-12), and 2,2-didecylpropane-1,3-bis-β-D-
maltopyranoside (lauryl maltose neopentyl glycol, LMNG). Low molecular weight 
heparin (LMWH, average molecular weight 3000 Da, sodium salt, from porcine sources) 
was purchased from P212121.com. Heparin Decasaccharide (DH) was purchased from 
Neoparin Inc. Antibodies for western blotting were mouse α-Myc monoclonal (9E10), 
which was isolated from hybridoma growth medium; rabbit α-Ihog polyclonal and mouse 
	   109	  
α-Hh monoclonal antibodies, which were gifts from P. Beachy; and appropriate HRP-
conjugated secondary antibodies. 
Buffers 
 Ni2+ Binding Buffer consisted of 35 mM NaH2PO4, 300 mM NaCl, and 15 mM 
imidazole adjusted to pH 8.0 with NaOH at 25°C. Ni2+ Wash Buffer consisted of 10 mM 
Tris base, 10 mM Tris HCl, and 300 mM NaCl. Ni2+ Elution Buffer was Ni2+ Wash 
Buffer with 250 mM imidazole. Strep Wash Buffer was 20 mM MOPS, 10 mM NaOH, 
and 200 mM NaCl. Strep Elution Buffer was Strep Wash Buffer with 2.5 mM 
desthiobiotin. Pull-Down Buffer was Strep Wash Buffer containing 0.01% LMNG and 
0.2 mM TCEP. CD Buffer was 10 mM NaH2PO4, 150 mM NaF, titrated to pH 7.2 with 
NaOH. CPM Thermal Stability Buffer was 20 mM HEPES pH 7.5, 200 mM NaCl, 0.02% 
LMNG. 
Proteins and expression vectors 
 IhogFn1, IhogFn2, IhogFn12 and IhogFn12ΔH are the first, second, or both Type III 
Fibronectin (FnIII) domains from Ihog, respectively, with ΔH referring to an Ihog surface 
mutant with reduced heparin binding (McLellan, 2006). BOCFn3, BOCFn23 and 
BOCFn13 are FnIII domains 3, 2–3, and 1–3 respectively from BOC. These BOC and 
Ihog fragments were expressed as His-Myc-TEV- (HMT-) fusion proteins using the 
vector pT7HMT (Geisbrecht, 2006) HhN, ShhN and ShhN-SC (The “Surface C” mutant 
of ShhN (Fuse, 1999), which is deficient in binding to Ptc-expressing cells) were 
subcloned into a modified version of pMAL-c2x as described (McLellan, 2008). ShhFL 
and HhFL are the full-length Mouse and Drosophila Hh proteins including native signal 
sequences and C-terminal self-splicing domains. IhogFn12TM consisted of the native 
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Ihog signal sequence followed by the first and second FnIII domains and the 
transmembrane region, but with the intracellular region truncated. Ski and Hhat are the 
entire native Hh acyltransferases from Drosophila and Mouse, respectively. MmHhip 
consisted of the β-propeller and following two EGF domains of Mouse Hhip. Drosophila 
Patched and mouse Patched-1 proteins are the tagged Mouse and Drosophila Ptc proteins 
with their C-termini truncated immediately after the final predicted transmembrane helix 
(DmPtcT1 and MmPtcT1, respectively).  
 DmPtcT1 and MmPtcT1 proteins were expressed fused to a concatenated series of N-
terminal tags including the Streptavidin Binding Peptide (SBP) (Keefe, 2001) an HRV3C 
protease site, a 6×His tag, a Myc tag, and a TEV protease site. Tags and Ptc proteins were 
cloned into the transfer vector pFastBac1 (Invitrogen). For co-expression of ShhFL with 
Hhat, HhFL with Ski, and DmPtcT1 with IhogFn12TM, transfer vectors were constructed 
from pFastBacDual (Invitrogen). Hhip was cloned into a modified pFastBac1 vector 
containing the Honeybee Mellitin (HBM) signal sequence to target for secretion, 
followed by 8×His, SBP, Myc and TEV sequences. 
Production of recombinant baculoviruses 
 Recombinant bacmids and baculoviruses for insect cell expression were constructed 
using the Bac-to-Bac system (Invitrogen) following manufacturer’s instructions. After 
transfecting Sf9 cells with bacmid DNA, the secreted virus (designated P1) was amplified 
two more times (P2 and P3 viruses) following manufacturer’s instructions. P3 virus was 
used for protein production. 
Bacterial expression and purification of HhN, IhogFn1, IhogFn2, IhogFn12, 
IhogFn12ΔH, ShhN, ShhN-SC, BOCFn3, BOCFn23 and BOCFn13 
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 All expression plasmids were transformed into BL21 and plated on LB with 
appropriate antibiotics. Single colonies were picked, grown overnight, and used to 
inoculate TB in baffled flasks at 225 RPM and 37°C. Bacteria were grown to an optical 
density (600 nm) of around 0.8, at which point the incubator temperature was lowered to 
16°C and the cultures allowed to shake for an additional hour. IPTG was then added to a 
final concentration of 0.5 mM, followed by expression for 24 hr. Bacteria were harvested 
by centrifugation and cell pellets stored at -20°C or -80°C. 
 Individual bacterial pellets were resuspended in ice-cold Ni2+ Binding Buffer 
containing 0.1 μL/mL Benzonase Nuclease and 1 mM PMSF. Bacteria were then lysed 
using a French press, and extracts cleared by centrifugation and syringe filtration. All 
proteins were initially purified using 5 mL HisTrap columns (GE Healthcare) charged 
with Ni2+. Where appropriate, tags were then removed by addition of His-tagged TEV or 
HRV3C and overnight incubation at 4°C. HhN, IhogFn12, IhogFn12ΔH, IhogFn1, and 
ShhN were then further purified by cation exchange chromatography as described 
(McLellan, 2006; McLellan, Zheng, Hauk, Ghirlando, Beachy, & Leahy, 2008). All 
proteins were desalted if necessary, then separated from tags and proteases by another 
round of HisTrap purification. All proteins were purified by a final size exclusion 
chromatography (SEC) step in Pull-Down Buffer, except for BOCFn13 for which the 
concentration of NaCl was 500 mM. 
Insect expression and purification of Hhip, DmPtcT1 and MmPtcT1 
 Sf9 and High Five cells were adapted and grown in suspension using a modification 
of the serum-free medium ISFM (Inlow, Shauger, & Maiorella, 1989) containing 10 g/L 
glucose instead of 2.5 g/L. Sf9 or High Five cells were grown or split to a concentration 
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of 2.0×106 cells/mL in air-sparged 1 L spinner flasks before infection with 20 mL of P3 
baculovirus (for simultaneous infection with multiple viruses, 20 mL of each virus were 
added). 
 Hhip was expressed in High Five cells. After infection, expression was allowed to 
proceed for 72 hr before removing the cells by centrifugation. The conditioned medium 
was then adjusted to pH 8.0 with NaOH, resulting in a heavy precipitate of calcium 
phosphate that was removed by centrifugation and filtration. Up to 6 L of pH-adjusted, 
clarified medium was flowed by gravity through 15 mL of “Complete His” resin (Roche) 
at room temperature overnight, which was then washed and eluted using manufacturer’s 
recommended conditions. Eluted protein was further purified using a 5 mL StrepTrap 
column (GE Healthcare), and tags were cleaved by addition of TEV protease overnight. 
Cut tags, uncleaved fusion protein and TEV protease were then removed using a 5 mL 
HisTrap column, and the remaining Hhip was further purified by SEC. 
 MmPtcT1 and DmPtcT1 were expressed in Sf9 cells. After infection, expression was 
allowed to proceed for 72 hr before harvesting cells by centrifugation. If not used 
immediately, cell pellets were stored by washing with PBS containing 10% glycerol, 
followed by snap freezing in liquid nitrogen and storage at -80°C. Cells were 
resuspended to a final volume of 30 mL per L of culture with Ni2+ Bind Buffer containing 
0.5 mM TCEP, 0.1 μL/mL Benzonase and one Complete Protease Inhibitor tablet, 
EDTA-free (Roche). Cells were lysed by French press, and nuclei and large debris 
removed by centrifugation at 10,000 rpm for 10 min in an SA-600 rotor. The supernatant 
was then transferred to a thin-walled ultracentrifuge tube and additional buffer added up 
to the maximum tube volume, around 40 mL, and centrifuged in an sw-28 rotor at 28,000 
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rpm for 1 hr to pellet membranes. Isolated membranes were weighed, added to 10 mL of 
Ni2+ Bind buffer per gram of membrane pellet, and resuspended using a Dounce 
homogenizer. 1 mL of 10% FC-12 per gram of membrane pellet was then added to the 
resuspended membranes, which were allowed to solubilize for 30 minutes on ice. Finally, 
detergent-solubilized protein was clarified with an additional ultracentrifugation spin. 
 Solubilized Ptc was applied to a 5 mL HisTrap column, washed with 50 mL of Nickel 
Wash Buffer supplemented with 0.2 mM TCEP and 0.02% LMNG, and eluted with 
Nickel Elution Buffer supplemented with 0.2 mM TCEP and 0.02% LMNG. A small 
amount of the reducing agent TCEP was added to prevent unwanted disulfide formation 
between exposed intracellular cysteines.  At this point, purified Ptc could be incubated in 
batch with a Strep-Tactin bead slurry for use in pulldown assays. Alternatively, to obtain 
higher concentrations and purity for Circular Dichroism (CD), analytical SEC, or for 
pulldown by ShhN- or HhN-coupled beads, an additional round of purification was 
performed using a 5 mL StrepTrap HP column. Purified Ptc from the nickel column was 
applied to the StrepTrap column, washed with Strep Bind Buffer supplemented with 0.2 
mM TCEP and 0.01% LMNG, and eluted with Strep Elution Buffer containing 0.2 mM 
TCEP and 0.01% LMNG. For Ptc proteins intended for CD, the Strep-Tactin purification 
buffers were substituted with CD Buffer containing the same amounts of TCEP, LMNG 
and desthiobiotin. For Ptc proteins intended for 7-diethylamino-3-(4’-maleimidylphenyl)-
4-methylcoumarin (CPM) thermal melts, Ptc was purified as described above with the 
following modifications: 2 mg/ml iodoacetamide was added at membrane solubilization; 
all subsequent buffers did not include TCEP; and protein from Nickel column elution was 
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desalted using a 5mL HiTrap desalting column equilibrated in CPM Thermal Stability 
Buffer. Freshly purified protein was used the same day for CPM thermal melt assays. 
Size exclusion chromatography of detergent-exchanged Ptc 
For each detergent screened, a membrane pellet expressing MmPtcT1 from 125 
ml Sf9 culture was used. Membrane pellets were solubilized in 1% fos-choline 12 as 
described in Methods.   Solubilized membranes were loaded onto a 1 mL HiTrap Nickel 
column.  The column was washed with 20 column volumes of buffer containing 20 mM 
Tris pH 8.0, 300 mM NaCl, 50 mM imidazole, 0.2 mM TCEP and 0.1% fos-choline 12.  
Bound protein was eluted in 10 column volumes of elution buffer containing 20 mM Tris 
pH 8.0, 300 mM NaCl, 250 mM imidazole, 0.2 mM TCEP and the greater of 2 × C.M.C. 
or 0.05% (w/v) of the detergent of interest.  Nickel elutions in the detergent of interest 
remained at 4°C overnight and the next day were injected onto a Superose6 column.  The 
Superose6 column was pre-equilibrated in 20 mM Tris pH 8.0, 300 mM NaCl, 0.2 mM 
TCEP and the detergent of interest at the indicated concentration (w/v) as follows.  
Detergents screened included octyl maltoside (1.78%), dodecyl maltoside (0.05%), decyl 
maltoside (0.345%), Cymal 4, Cymal 5 (0.24%), Cymal 6 (0.06%), Cymal 7 (0.05%), 
octyl glucose neopentyl glycol (0.12%), decyl maltose neopentyl glycol (0.05%), and 
lauryl dimethylamine N-oxide (0.05%). 
Immunostaining and confocal microscopy of Patched-expressing Sf9 cells 
Sf9 cells were plated on gelatinized glass coverslips in 6-well plates and 
simultaneously infected with the indicated viruses.  Expression was allowed to proceed 
for 24-36 hours.  All steps were performed at room temperature unless otherwise noted.  
Cells were fixed by adding to the growth medium an equal volume of PFA (4% 
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paraformaldehyde in PBS) for 5 min, followed by aspiration and addition of undiluted 
PFA for another 5 min.  Cells were then permeablized with 0.5% Tween-20 in PBS for 
15 min, and blocked with PBST (PBS with 0.1% Tween-20) containing 1% BSA for 30 
min.  Staining was performed with α-Myc (1:200 in blocking solution) at 4°C overnight.  
Staining solution was removed and cells washed 3 times with PBST, incubating for 5 
minutes each wash.  Finally, cells were incubated in the dark for 1 hour with fluorescent 
secondary antibody solution (Cy3 Goat α-Mouse, 1:1000 in blocking solution), washed 3 
times with PBST, and coverslips mounted on glass slides in aqueous mounting medium 
for confocal microscopy. 
Cell-free binding assay  
 Cell-free binding assay was performed as in (Zheng, 2010).  In brief, isolated 
membrane pellets from uninfected Sf9 cells or cells infected with MmPtcT1 baculovirus 
were resuspended in ShhN-Renilla conditioned medium.  After 1 hr incubation, 
membranes were reisolated by centrifugation, washed three times with ice cold PBS, and 
solubilized in 250μl passive lysis buffer (Promega) and 5μL of lysate used to measure 
Renilla luciferase activity. 
Ptc characterization 
 The behavior of Ptc proteins was analyzed by CD, CPM fluorescence thermal 
stability assays, and by analytical SEC using a Superose6 column. For CD analysis, 
spectra were collected at 4°C between 185 nm and 280 nm, using Ptc proteins in a 
cuvette with 1 mm pathlength. Thermal unfolding analysis was also performed by 
following the CD signal at 208 nm while increasing the temperature from 4°C to 95°C. 
CPM fluorescence thermal stability assays were performed as in (Alexandrov, Mileni, 
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Chien, Hanson, & Stevens, 2008). In brief, a 1:40 dilution of a 4 mg/ml solution of CPM 
dye (Invitrogen) in DMSO was incubated in CPM Thermal Melt Buffer for 5 min at room 
temperature, protected from light. Ptc protein (10 μg) was diluted in CPM Thermal Melt 
Buffer to a final volume of 290 μL. After 5 min at room temperature, 10 μL of dilute dye 
was added and the sample was mixed and transferred to a quartz fluorometer cuvette. The 
cuvette was transferred to a Fluorolog-3 spectrofluorometer (Horiba Jobin Yvon) 
equipped with a Peltier sample cooler (F-3004) and heated at a rate of 2°C/min. Emission 
at 463 nm was monitored with an excitation wavelength of 387 nm from 20°C to 80°C. 
For SEC analysis, Ptc was injected onto a Superose6 column equilibrated in Pulldown 
Buffer. Its elution profile was followed by UV absorption at 280 nm, and apparent 
molecular weights were estimated by comparison to Gel Filtration Standards (Bio-Rad). 
Pulldown Assays 
 Bead-based pulldown assays were used to screen for interactions between purified, 
detergent-solubilized Ptc and other proteins. All steps were carried out on ice or at 4°C 
unless otherwise noted. Immediately after performing the nickel purification, Ptc resin 
was prepared by coupling the SBP-tagged protein to Strep-Tactin resin (IBA). An excess 
of Ptc protein solution (typically the elution peak from an entire 1 L prep) was added to 
enough Strep-Tactin resin to give 10 μL of Ptc resin for each desired pulldown condition; 
typically, this resulted in 2–5 μg of coupled Ptc protein per condition. Ptc was allowed to 
couple to completion for 2 hr. Resin was then pelleted and resuspended in Pulldown 
Buffer, divided into separate tubes, and pelleted, such that 10 μL of packed Ptc resin were 
obtained in each tube. Pulldowns were set up in a total volume of 50 μL using the 
reaction compositions specified in Figure 4.4 and 4.4. Generally, pulldown conditions 
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contained 10 μM of each soluble protein, and around 0.75 μM of Ptc. These binding 
reactions were incubated for 1 hr. Ptc beads were then washed 4 times with 1 mL of 
Pulldown Buffer, and Ptc was eluted by adding 20 μL of Pulldown Buffer supplemented 
with 2.5 mM biotin. The presence of proteins that bound and eluted with Ptc was then 
analyzed using Coomassie-stained SDS-PAGE gels and Western blots. 
Co-purification of Ptc with other proteins 
 Ptc proteins were co-expressed with potential partners by infecting Sf9 cells with the 
following viruses or combinations of viruses: MmPtcT1 virus with ShhFL/Hhat dual 
expression virus; DmPtcT1/IhogFn12TM dual expression virus; DmPtcT1 virus with 
HhFL/Ski dual expression virus; and DmPtcT1/IhogFn12TM dual expression virus with 
HhFL/Ski dual expression virus. In each case, the Ptc protein was fused with N-terminal 
SbpPHMT tags, and its potential binding partners were untagged. Sequential nickel, 
Strep-Tactin, and Superose6 chromatography steps were performed as outlined above, 
and the presence of co-purifying complexes evaluated by Coomassie-stained SDS-PAGE 
and Western blot. 
 
Results 
Ptc Purification and Characterization 
 Both Drosophila and Mouse Ptc expressed at levels of 0.5 – 3 mg of protein per liter 
of Sf9 cell culture.  Confocal imaging of infected Sf9 cells expressing Ptc proteins 
indicated that Ptc was present at the cell surface, and membranes isolated from 
MmPtcT1-expressing cells bound Shh (Figure 4.1).  Detergent solubilization trials 
indicated, however, that Ptc proteins were only solubilized well by the fos-choline class 
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of detergents, and FC-12 was selected for routine extraction. Solubilized Ptc proteins 
were purified by a combination of Nickel and Strep-Tactin affinity chromatography 
(Figure 4.3A). Yields of purified Ptc ranged from 20–50% of total expressed protein as 
judged by Coomassie-stained gels and comparison to BSA standards. Losses resulted 
from incomplete solubilization, incomplete capture, or incomplete elution from Nickel 
and were dependent on flow rates and the amount of protein present initially. Although 
most detergents do not solubilize Ptc proteins efficiently, we found that once Ptc had 
been solubilized, FC-12 could be exchanged for a variety of other detergents during the 
initial HisTrap purification. We therefore evaluated the behavior of Ptc proteins by SEC 
after exchange into different detergents (Figure 4.2). SEC behavior was qualitatively 
similar for most detergents tested, with a species eluting as a small oligomer, potentially 
consistent with a trimer (Lu, 2006) (Fig. 4.3B, arrow 1); a higher-order oligomer (arrow 
2); and a small proportion in the void volume. Although the SEC behavior of Ptc after 
purification is similar in many detergents, Ptc in LMNG was less prone to precipitation 
over several days of storage.  All binding studies were therefore carried out with Ptc 
exchanged into LMNG. 
 Characterization of purified Ptc proteins by CD spectroscopy revealed spectra typical 
of proteins with high alpha-helical content (Figure 4.4C). The secondary structure content 
of DmPtcT1 calculated from its CD spectrum was 47% helix and 13% sheet, similar to 
the values of 44% and 6% predicted from the primary sequence by PSIPRED (McGuffin, 
2000) CD at 208 nm was used to follow unfolding of DmPtcT1, giving an unfolding 
midpoint of 58°C. We also followed Ptc unfolding using CPM dye, a measure that is 
more closely related to tertiary rather than secondary structure. By this method, unfolding 
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midpoints were 36°C and 37°C for MmPtcT1 and DmPtcT1, respectively (Fig. 4.2D).  
Deglycosylation of purified MmPtcT1 with PNGaseF also resulted in a small but visible 
band shift on Coomassie-stained SDS-PAGE, consistent with the molecular weight of 
several glycans; MmPtcT1 contains 6 consensus N-linked sites, with total expected 
glycan mass of 6-7 kDa, assuming pauci-mannose glycosylation profiles typical of Sf9 
cells (Aeed & Elhammer, 1994). These results are consistent with proper processing and 
membrane localization of expressed Ptc proteins. 
Pulldown of potential binding partners by MmPtcT1 
 MmPtcT1-coupled resin was tested for its ability to pull down soluble ShhN, ShhN-
SC, HMT-BOCFn3, HMT-BOCFn23 and HMT-BOCFn13 individually as well as in 
ternary combinations (Figure 4.4). 1 mM Ca2+ was included in most conditions as Ca2+ is 
known to be required for ShhN binding to BOCFn3. 200 μM LMWH was included in one 
condition with BOCFn13 and ShhN, since both are known to be heparin-binding proteins. 
We also included conditions with 5 mM EGTA, a Ca2+ chelator, as a control to eliminate 
ShhN:BOCFn13 binding. Finally, we included Hhip in certain conditions to test its ability 
to block potential binding of ShhN to MmPtcT1. Strep-Tactin resin without conjugated 
MmPtcT1 (Figure 4.4) or with the tagged, irrelevant membrane protein AcrB conjugated 
was used as a control for nonspecific binding. We used Coomassie-stained SDS-PAGE to 
detect bound proteins, with Western blots also performed in some cases to detect weakly-
bound proteins and confirm the identities of Coomassie-stained protein bands. 
 ShhN did not bind to detectably to MmPtcT1 beads as judged by Coomassie-stained 
SDS-PAGE gels of the eluted samples. Trace levels of ShhN binding to MmPtcT1 beads 
were detectable only by Western blotting; this binding was eliminated by EGTA. ShhN 
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and BOCFn13 visibly precipitate in the presence of LMWH and Ca2+, resulting in high 
nonspecific binding to beads; we could therefore not evaluate specific binding of this 
complex to MmPtcT1. Since BOCFn13 and ShhN bind each other with micromolar 
affinity and each independently binds heparin, this precipitation was probably due to 
heparin-mediated protein crosslinking. Interactions between ShhN and MmPtcT1 beads 
were not enhanced by the presence of any BOC fragment, whether in the presence or 
absence of LMWH or Ca2+. Binding of ShhN to MmPtcT1 beads was also unaffected by 
the presence of Hhip. 
 By Western blot analysis, ShhN did not adhere to MmPtcT1 resin to a greater degree 
than the negative control surface mutant ShhN-SC. However, ShhN-SC showed no 
dependence on EGTA and no precipitation in the presence of LMWH and HMT-
BOCFn13, consistent with its inability to bind BOC (Figure 4.4).  
 HMT-BOCFn13 and HMT-BOCFn23 were not specifically pulled down by 
MmPtcT1-coupled beads. Although MmPtcT1-coupled beads did pull down BOC 
proteins as compared to blank beads (Figure 4.4), we observed that this binding was 
dependent on the presence of 1 mM Ca2+ and was eliminated by EGTA, despite the lack 
of known calcium binding to BOC proteins. We therefore performed additional control 
experiments comparing the binding and solution behaviors of tagged and untagged BOC 
proteins in the presence of calcium. These experiments showed that (i) His-tagged 
proteins oligomerize in the presence of 1 mM Ca2+ and that (ii) the binding of HMT-
BOCFn13 to MmPtcT1 was dependent on the presence of His tags on both proteins. An 
irrelevant His-tagged protein was pulled down equally well by MmPtcT1 beads, and 
BOC proteins could also be pulled down equally by beads coupled with the irrelevant 
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His-tagged membrane protein AcrB. The presence of ShhN or ShhN-SC did not enhance 
the binding of BOC proteins to MmPtcT1 beads, nor did the addition of LMWH (Figure 
4.4). 
 We also performed the pulldown experiments in reverse by coupling ShhN and 
ShhN-SC to beads and attempting to pull down detergent-solubilized MmPtcT1 alone or 
in the presence of HMT-BOCFn3 and HMT-BOCFn13. Hhip was added to test for its 
ability to block potential Ptc binding, and soluble ShhN and ShhN-SC were added as 
specific competitors for Ptc binding to ShhN- and ShhN-SC-coupled resins. Consistent 
with our previous results (Figure 4.4), we observed no binding above background of 
MmPtcT1 to ShhN resin. Aside from MmPtcT1, the resins pulled down the expected 
binding partners: ShhN resin pulled down BOCFn3 and HMT-BOCFn13 in a Ca2+ 
dependent manner, and pulldown of HMT-BOCFn3 by ShhN was blocked by Hhip. 
Pulldown of potential binding partners by DmPtcT1 
 We next used similar pulldown assays to screen for DmPtcT1 binding to potential 
partners. DmPtcT1-coupled beads were used to pull down HhN, IhogFn12, IhogFn12ΔH, 
IhogFn1 and IhogFn2. These proteins and their combinations were not found to interact 
strongly or specifically with DmPtcT1-coupled beads. Although IhogFn1, IhogFn12 and 
IhogFn12ΔH were pulled down by DmPtcT1 beads in the absence of LMWH and could 
be detected in Coomassie-stained gels (Figure 4.5), this binding was only slightly greater 
than binding to the irrelevant membrane protein AcrB. In the presence of 200 μM 
LMWH, mixing IhogFn1 or IhogFn12 with HhN induced visible precipitation, resulting 
in high non-specific binding to Strep-Tactin resin. We therefore could not evaluate 
specific binding to DmPtcT1 resin in these conditions. However, substituting 200 μM 
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decaheparin (DH) for LMWH prevented the precipitation of IhogFn1 and HhN and 
eliminated binding of IhogFn1 to DmPtcT1. HhN binding to DmPtcT1 beads was not 
detectable on Coomassie-stained gels except in the cases where precipitation was present.  
By Western blotting HhN did not bind DmPtcT1 beads specifically or to a greater degree 
than uncoupled Strep-Tactin beads. The presence of IhogFn1 and DH with HhN did not 
enhance the binding of HhN to DmPtcT1 beads. 
 Finally, we coupled HhN to amylose resin, and attempted to pull down soluble 
DmPtcT1. We also tested for binding to HhN of combinations of DmPtcT1 with 
IhogFn1, IhogFn2, IhogFn12, and IhogFn12ΔH, and with soluble non-conjugated HhN 
(as a specific competitor for DmPtcT1 binding to HhN beads). No binding of DmPtcT1 
was detectable in any condition, even when assessed by Western blotting. Aside from 
DmPtcT1, the HhN resin pulled down its known binding partners as expected: IhogFn1 
and IhogFn12 in a heparin-dependent manner, and IhogFn12ΔH much more weakly than 
IhogFn12. As expected, the HhN resin did not pull down IhogFn2. 
Co-expression and purification of Ptc proteins with potential binding partners 
 Since Drosophila Ptc is believed to exist as a co-receptor complex with Ihog (Zheng, 
Mann, Sever, & Beachy, 2010), we investigated whether the co-expression and 
purification of IhogFn12TM with Ptc resulted in improved binding or better 
monodispersity of Ptc as judged by SEC. In addition, since the Hh proteins used in our 
pulldown assays were expressed in E. coli, they lacked lipid modifications. We therefore 
also investigated the co-expression and purification of Ptc proteins with dually lipidated 
Hh proteins, referred to as HhNP and ShhNP. These were expressed using dual-expression 
HhFL/Ski and ShhFL/Hhat baculoviruses, which simultaneously drive expression of the 
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full-length Hh proteins together with their respective palmitoyltransferases, although we 
did not determine whether HhNP or ShhNP were palmitoylated. 
 Co-expression of proteins did not result in co-purified stoichiometric complexes that 
interact strongly. When Sf9 cells were infected with a dual DmPtcT1/IhogFn12TM virus, 
both proteins were well-expressed. DmPtcT1 was purified using the standard Ni2+/Strep 
procedure (Figure 4.5A) and the resulting purified protein was separated by analytical 
SEC (Figure 4.5B). As judged by Western, some IhogFn12TM bound and eluted with 
DmPtcT1 during each purification step,  but with significant amounts dissociating during 
each wash step. Comparison of the Ihog Western band intensities to standards (data not 
shown) indicated that the amount of IhogFn12TM remaining after DmPtcT1 purification 
was sub-stoichiometric with respect to DmPtcT1. The SEC behavior of DmPtcT1 co-
expressed with IhogFn12TM was similar to that of DmPtcT1 expressed alone.  
Coomassie-stained SDS-PAGE and Western blotting of the SEC fractions indicated that 
DmPtcT1 and IhogFn12TM elution peaks overlapped, but with IhogFn12TM eluting at 
slightly higher apparent molecular weight. 
 When DmPtcT1 and HhNP were co-expressed, HhNP was observed to co-purify with 
DmPtcT1 (Figure 4.6A), with some losses during each affinity step.  SEC followed by 
SDS-PAGE and Western blotting showed that the elution profile of HhNP was very 
broad, and its peak did not track the elution of DmPtcT1.  Co-expression of all three 
proteins (DmPtcT1/IhogFn12TM with HhNP) did not appreciably alter the co-purification 
or SEC behavior of any protein. 
 Similarly, MmPtcT1 was co-expressed with ShhNP and purified (Figure 4.7A).  
Significant amounts of ShhNP remained in the flow-through during each affinity step, and 
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although some residual protein co-purified with MmPtcT1 and was detectable by 
Western, it was not visible on Coomassie-stained gels.  By Western, the concentration of 
ShhNP clearly decreased during each affinity step, while the concentration of MmPtcT1 
increased.  The behavior of MmPtcT1 on SEC was not significantly altered by co-
expression with ShhNP, and the elution peak of ShhNP did not match the peak of 
MmPtcT1 (Figure 4.7B). 
 
Discussion 
 In this study, mouse Patched-1 and Drosophila Patched proteins were expressed in 
Sf9 cells, detergent solubilized, purified, and characterized by SEC and CD. Deglycosy-
lation and confocal microscopy studies suggested that Ptc proteins were glycosylated and 
transported to the cell surface, and Sonic Hedgehog from conditioned medium bound to 
MmPtcT1 in membranes isolated from MmPtcT1-expressing Sf9 cells.  Detergent-
extracted and purified Ptc proteins contained the expected secondary structure content as 
judged by CD but eluted as multiple species SEC with one peak consistent with a trimer 
or small oligomer and another of higher apparent molecular weight.   
 Despite our observations that Ptc proteins behaved as expected by CD, cell surface 
expression, and deglycosylation analysis, and that some purified protein ran at sizes 
potentially consistent with physiological oligomers by SEC, high-affinity binding to 
cognate Hh proteins or Ihog/BOC co-receptors could not be detected. Recent studies 
indicate that Ptc proteins have an absolute requirement for co-receptors to signal 
(BOC/CDO/Gas1 in mammals, Ihog/BOI in Drosophila), and that Ptc forms physical 
complexes with these co-receptors (Zheng, 2010; Izzi, 2011; Allen, 2011). In addition, 
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high-affinity binding of Shh to cells is Ptc-dependent (Fuse, 1999; Marigo, 1996). We 
were therefore surprised not to detect high-affinity binding between purified Ptc proteins 
and any of these putative binding partners, either pairwise or in ternary combinations. 
 While some bound ShhN was detected in Western blots after saturating amounts were 
incubated with MmPtcT1 beads, the amount of ShhN detected was not convincingly 
above levels of nonspecific binding to blank beads (Figure 4.4). Based on the clearly 
observed binding of BOC/Ihog proteins to their cognate Hh proteins in our pulldown 
assays and their known Kd’s of ~ 2.5–5 μM, we expect interactions between Ptc proteins 
and any partner would have resulted in the clear observation of Hh on Coomassie-stained 
gels if their Kd were below ~5 μM. Furthermore, the surface mutant ShhN-SC, which has 
impaired binding to Ptc-expressing cells (Fuse, 1999), showed roughly the same trace 
levels of binding to MmPtcT1 beads as native ShhN. The addition of Hhip also did not 
compete with Ptc beads for ShhN binding, further suggesting a lack of specific binding of 
ShhN to MmPtcT1 beads. Thus, we were not able to reproduce a previous observation of 
high-affinity binding between ShhN and purified mouse Ptc (Joubert, 2009). In addition, 
HMT-BOCFn13 and HMT-BOCFn23 did not bind specifically to MmPtcT1. Binding in 
initial studies in the presence of Ca2+ proved to be mediated by His tags (all BOC and Ptc 
proteins, but not Ihog proteins, were His-tag fusions) in the presence of Ca2+ ions. The 
presence of Shh together with BOC fragments did not alter the apparent binding of any of 
these proteins to MmPtcT1, providing no evidence for the presence of a ternary complex 
between soluble forms of BOC and Shh and detergent-solubilized Ptc. 
 Drosophila HhN also did not bind DmPtcT1 beads at levels appreciably above 
background, as judged by Western blotting. No HhN was detectable on Coomassie-
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stained gels. IhogFn1, IhogFn12, and IhogFn12ΔH were bound by DmPtcT1 beads in the 
absence of both heparin and Hh, as detected by Coomassie-stained gels; however, for 
IhogFn12, roughly comparable binding was also seen to beads coupled with the irrelevant 
membrane protein AcrB. The addition of HhN and heparin decasachharide eliminated 
binding of IhogFn1 to DmPtcT1 beads. In contrast with previous observations (Zheng, 
2010), no binding of IhogFn2 to DmPtcT1 beads was observed. In all cases where some 
interaction was observed, the relative stoichiometry of the bound protein to Ptc was low, 
as judged by comparing Coomassie band intensities. Given the low stoichiometry of all 
observed complexes and the nonspecific binding seen between IhogFn12 and AcrB, we 
conclude that specific binding of Ihog fragments to Ptc was not observed. 
 As a final effort at purifying high-affinity, stoichiometric complexes of Ptc proteins 
with putative ligands, we attempted several co-expression experiments: MmPtcT1 with 
ShhNP, DmPtcT1 with HhNP, DmPtcT1 with IhogFn12TM, and DmPtcT1 with HhNP and 
IhogFn12TM. In all cases, as Ptc proteins were purified using His and SBP tags, their 
expression partners increasingly dissociated with each chromatographic step. A final 
Superose6 chromatography step showed some proportion of binding partner co-migrating 
with Ptc in each case, but with most having been lost in preceding purification steps. 
Qualitatively, this suggests at most a weak interaction between purified Ptc and these 
binding partners. 
 The absence of high-affinity interactions between purified Ptc and several potential 
binding partners observed here could be explained in several ways. Firstly, Ptc may not 
adopt a native or binding-competent conformation in this expression system, or it may 
lose these properties during detergent solubilization.  The ability of both Ptc proteins to 
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reach the cell surface and of MmPtcT1 to become glycosylated and bind ShhN when Sf9 
cell membranes suggests initial folding and biogenesis occurs properly (Figure 4.1), 
however, and that any non-native structure is more likely to stem from detergent 
solubilization.  Regrettably, no functional assay exists to validate the integrity of purified 
Ptc—indeed, the central objective of our studies was to find an in vitro activity for Ptc 
that could be studied—and we can only rely our CD and SEC results to conclude that 
purified Ptc retains at least some native-like structure. 
 Although fos-choline detergents are generally considered harsher detergents that may 
destabilize membrane proteins during solubilization—a particular concern for proteins 
like Ptc that are only efficiently extracted by fos-choline detergents—many membrane 
proteins retain function in fos-choline. Proteins have been crystallized directly from fos-
choline detergents, for example, including alpha helical membrane proteins [43]. The 
transmembrane protein SCAP was also only extracted well by a fos-choline detergent and 
was shown to retain function in detergent-extracted form.  SCAP is similar to Ptc in being 
a multi-pass transmembrane protein (a tetramer of 8-pass subunits) with a sterol-sensing 
domain and was also expressed in Sf9 cells with N-terminal tags.  If Hh proteins interact 
with a region of the large, presumably independently-folded extracellular loops of Ptc as 
has been suggested, these regions of Ptc may also be less susceptible to destabilization by 
detergents than the Ptc transmembrane regions.  
Another possibility for the absence of strong binding between Ptc and cognate Hh and 
CDO/Ihog proteins is that additional cell-surface co-factors not present in our assays are 
required for high-affinity interactions or to maintain Ptc stability.  The low concentration 
of luciferase-tagged Shh in the conditioned medium used to show binding between Shh 
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and mPtc in isolated Sf9 membranes precluded saturation of binding and estimation of a 
binding constant, but the likely absence of mammalian co-factors in these cells suggests 
that mPtc itself can bind Shh with measurable affinity in the absence of known co-
factors.  A requirement for a bilayer environment, particular lipids, or glycans remains a 
possibility, however.  Our inability to observe high-affinity binding between Ptc and 
cognate Hh or Ihog/CDO homologs thus seems likely to stem from loss of native-like Ptc 
function during detergent solubilization or detergent disruption of ShhN binding ability.  
As biochemical characterization of the nature and components of the functional Hh 
receptor remains a key objective of studies aiming to understand Hh signaling in normal 
and disease states, it will be important aspect of future efforts will be to find purification 
conditions that preserve or restore Ptc function.  Nonetheless, the ability to produce near 
milligram amounts of purified Ptc described here establishes a cornerstone for future 






Figure 4.1 Functional Ptc expresses on the surface of Sf9 cells.  (A) Sf9 cells infected 
with the indicated viruses were immunostained using anti-Myc (9E10) primary and Cy3 
secondary antibodies (red), and imaged by confocal microscopy.  Nuclei were stained 
with DAPI (blue). (B) Membranes from uninfected Sf9 cells or cells infected with 
MmPtcT1 virus were isolated, incubated with varying concentrations of ShhN-Renilla 
luciferase conditioned medium, washed, and residual luciferase activities determined. 
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Figure 4.2 SEC of Ptc proteins after exchange into different detergents.  Superose6 
size-exclusion chromatograms of MmPtcT1 solubilized in fos-choline 12 and exchanged 
during purification into the indicated detergents are shown.  Similar behavior after initial 
purification was observed in most detergents and for DmPtcT1 (not shown), with an 
oligomeric Ptc peak eluting slightly before the 670 kDa marker, and in some cases 
another peak between the 158 and 670 kDa markers
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Figure 4.3 Purification and characterization of Ptc proteins. (A) DmPtcT1 and 
MmPtcT1 were purified by successive Ni2+ and Strep-Tactin (ST) chromatography steps. 
Gel Lanes: (M) resuspended membranes; (S) detergent-solubilized membranes; (F) flow-
through; (E) elution (B) SEC of purified, concentrated MmPtcT1 (140 kDa calculated) 
compared to tagged AcrB (123 kDa), a protein standard with the same predicted 
topology. MmPtcT1 elutes in two peaks: a small oligomer consistent with a potential 
physiological trimer (arrow 1) and a larger oligomer (arrow 2) (C) CD spectra of 
DmPtcT1 and MmPtcT1 show substantial alpha-helical character. (D) Thermal unfolding 
of Ptc proteins as measured by CD at 208 nm (correlated with alpha helical content) and 
by CPM dye binding to exposed cysteines.  
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Figure 4.4 Pulldown of potential binding partners by MmPtcT1.  The indicated 
proteins and cofactors were incubated with MmPtcT1-coupled Strep-Tactin resin and 
blank (uncoupled) Strep-Tactin resin.  Bound proteins were eluted with biotin and 
analyzed by Coomassie-stained SDS-PAGE.  
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Figure 4.5 Pulldown of potential binding partners by DmPtcT1.  Proteins and other 
cofactors were incubated with DmPtcT1-coupled Strep-Tactin resin and blank 
(uncoupled) Strep-Tactin resin in the indicated combinations.  Bound proteins were 
eluted with biotin and analyzed by Coomassie-stained SDS-PAGE and anti-Shh Western 
blot.  Shh and BOC fragments, marked with arrows, that appear to co-precipitate with Ptc 
proved to be due to heparin-dependent precipitation (Shh) or His-tag and Ca2+  dependent 
association (BOC).  	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Figure 4.6 Co-expression and purification of DmPtcT1 with potential binding 
partners. Sf9 cells were co-infected with baculoviruses driving expression of DmPtcT1 
along with IhogFn12TM, HhFL/Ski, or both IhogFn12TM and HhFL/Ski.  Expected 
positions of indicated protein bands are marked. (A) DmPtcT1 was purified and detected 
by Coomassie-stained SDS-PAGE.  The presence of co-purifying Hh or Ihog was 
followed by Western blot.  The same Western blot membrane was sequentially probed 
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with Ihog and Hh antibodies.  The images were then overlaid and color-coded (see key).  
Three major Hh bands are observed: one corresponding to the molecular weight of 
unprocessed Hh (Hh-FL), one corresponding to C-terminally processed Hh retaining its 
signal sequence (SigP-HhN), and one corresponding to HhNp. (B) The resulting co-
purified proteins were subjected to Superose6 SEC, and the fractions analyzed by 
Coomassie-stained SDS-PAGE (to visualize DmPtcT1) and by Western blot, probing 
sequentially for Hh and Ihog as in (A).  
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Figure 4.7 Co-expression and purification of MmPtcT1 with Shh. Sf9 cells were co-
infected with baculoviruses driving expression of MmPtcT1 along with ShhFL/Hhat.  (A) 
MmPtcT1 was purified and visualized with Coomassie-stained SDS-PAGE.  The 
presence of co-purifying Shh followed by Western blot. Two major Shh bands are 
observed: one corresponding to the molecular weight of the unprocessed Shh (ShhFL), 
and one corresponding to the expected molecular weight of ShhNp. (B) The resulting co-
purified proteins were subjected to Superose6 SEC.  The fractions were analyzed by 
Coomassie-stained SDS-PAGE for MmPtcT1 detection, and by Western blot for Shh.  
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